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Large bone defects pose a significant clinical challenge, aff cting large numbers 
of patients at high costs.  The current clinical standard fo  treating these defects is 
implantation of bone grafts.  While autograft bone is the gold standard for graft material, 
there is generally an insufficient amount available for treating large bone defects.  
Devitalized allograft bone from cadavers is more readily available; however this material 
displays limited integration with host bone resulting i as many as 1/3 of these grafts 
failing within 2-3 years after implantation.  Bone tissue engineering strategies aim to 
replace bone grafting procedures with treatment by a combination of a structural scaffold, 
biochemical cues, and / or cells capable of enhancing healing.  Cellular therapies may be 
of particular importance when treating large bone defects because many patients lack an 
adequate endogenous supply of osteogenic cells or osteoprogenitor c lls.   
The goal of this thesis was to quantitatively compare stem-cell based strategies for 
treating large bone defects.  First, we developed a challenging large bone defect model in 
immunocompromised rats for use as a reproducible test bed to quantitatively compare 
human stem cell-based therapies, and then we evaluated the abilities of adult and fetal 
stem cells to enhance defect healing when delivered on porous polymer scaffolds.  Our 
results showed that stem cell-seeded porous polymer scaffold therapy enhanced defect 
healing compared to treatment with acellular scaffolds alone in the absence of added 
osteogenic signals, but was insufficient to fully regenerate limb function.  Second, we 
sought to label stem cells with an in vivo tracking agent, the quantum dot, to determine 
biodistribution of delivered cells during the bone healing process.  We showed that while 
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quantum dots effectively label human stem cells in vitro and have negligible effects on 
cell viability and osteogenic differentiation i vitro, their use as a long term in vivo 
tracking agent was inconclusive due to uptake by host macrophages.  Post mortem 
immunohistochemistry analysis confirmed that at least a sm ll population of human cells 
remained at defect sites four weeks post implantation. Finally, we treated defects with 
both in vitro and in vivo osteogenic gene therapy approaches, using scaffolds coated with 
an adeno-associated viral (AAV) vector to encode the gene for the osteogenic signal bone 
morphogenetic protein 2 (BMP2) in human stem cells prior to implantation or in host 
defect cells after scaffold implantation.  Effective BMP2 gene transfer to stem cells and 
induction of osteogenic differentiation was first verified n vitro.  However, treatment of 
segmental defects with scaffolds containing BMP2-transduced st m cells (in vitro gene 
therapy) produced less robust healing than the in vivo gene therapy approach with 
scaffolds delivering the BMP2 gene to host cells.  
In conclusion, this work has produced a challenging and reproducible model of 
large bone defects that can be used to gain new insights into the cell-mediated defect 
repair process through quantitative comparison of human stem cell-based bone tissue 
engineering therapies.  This work has confirmed the therapeutic benefit of stem cell-
seeded construct delivery over acellular construct delivery for enhancement of defect 
healing in the absence of added osteogenic stimuli and suggested the therapeutic potential 
of fetal amniotic-fluid derived stem cells as an alternative to adult marrow-derived stem 
cells for treatment of large bone defects.  This work has refuted the ability of the 
fluorescent quantum dot to serve as an effective long termin vivo cell tracking agent, 
which will impact the choice of cell tracking agents used in future studies of cell-
 xx
mediated tissue repair therapies.  Finally, this work is the first to present proof of concept 
results of a true off-the-shelf, donor bone graft-free orthotopic large bone defect repair 
therapy in which pre-sized thermostable porous polymer scaffolds lyophilized with 
scAAV2.5-BMP2 could be frozen at length until needed for clinical implantation in large 






Motivation and Introduction 
Bone related injuries are a common problem faced by large numbers of patients at 
significant costs.  There are 150,000 wrist, hip, and vertebral fractures each year in the 
UK due to osteoporosis with an estimated cost of 17 billion p unds (Dawson and Oreffo 
2008). As the aging population grows, worldwide the number of annu l hip fractures 
alone is expected to rise from 1.7 million in 1990 to 6.3 million by 2050 (Dawson and 
Oreffo 2008).  In addition to bone injuries related to systemic conditions, local problems 
such as fracture nonunions and large bone defects present a challenging problem facing 
orthopaedic surgeons as well.  The normal healing response t  bone damage consists of 
initial inflammation, followed by soft then hard fracture callus formation, and finally 
bone remodeling (Khan, Yaszemski et al. 2008).  In fracture nonunions and large bone 
defects this healing does not occur or does so only to a limited extent, due to a variety of 
factors such as soft tissue damage, loss of vascularity, distraction of fracture fragments, 
soft-tissue interposition, malnutrition, infection, instability, periosteal stripping, and 
systemic disease such as rheumatoid arthritis (Tseng, Lee et al. 2008), (Kalfas 2001).  
Lack of healing creates a need for surgical intervention, a d thus out of the 
approximately 1.5 million bone-grafting operations performed annually in the United 
States (Einhorn 2003),  500,000 are for patients with nonunions or large defects (Bucholz 
2002).   
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There is currently no optimal clinical treatment for the repair of large bone 
defects.    Autograft bone is only available in limited volumes while allograft bone fails 
to integrate with host bone, creating a high rate of failure within a short period after 
implantation.  Bone tissue engineers aim to create a graft substitute possessing the 
benefits of both autograft and allograft without their drawbacks (Guldberg, Oest et al. 
2004) that could be used as a large bone defect treatment for rest ration of bone structure 
and function.  The general bone tissue engineering therapy consists of some combination 
of structural scaffold, bone forming cells, and biochemical signaling cues to increase 
bone formation.  Therapies delivering signaling cues through bolus delivery of osteogenic 
proteins have shown some therapeutic potential for healing large bone defects, but there 
are growing concerns over negative side effects such as infl mmation and ectopic bone 
formation that are associated with the large doses of delivered protein needed for 
improved repair (Cahill, Chi et al. 2009).  In light of these concerns, cell-based bone 
tissue engineering treatments present an attractive altern tive that may be especially 
important for treating large bone defects in patients lacking sufficient endogenous cell 
populations (Bruder 1999).  Stem cells are an attractive cell choice for bone tissue 
engineering therapies because they can proliferate to a large number of cells as well as 
differentiate into bone forming cells.   
While multiple systemic and local site-specific stem cell delivery methods have 
been investigated, the optimal delivery strategy is unclear and much about the 
relationship between delivery method and the stem cell-enhanced healing process 
remains unknown (Chamberlain, Fox et al. 2007).  Although a variety of stem cell 
sources have been investigated for bone repair in in vitro and ectopic in vivo models 
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(Zhang, Teoh et al. 2009), few comparative n vivo studies have been performed in 
orthotopic in vivo models which better represent clinical bone defects.   Furthermore, 
limited cell survival following implantation remains a key issue (Waese, Kandel et al. 
2008).    
The overall objective of this thesis was to establish a critically-sized rat femoral 
defect model in immunocompromised rats and then to effectively treat defects with 
human fetal and adult stem cell-based bone tissue enginering therapies, with the goal of 
restoring bone structure and function.  The central hypothesis was that stem cell-based 
tissue engineering therapies would enhance defect bone regeneration over comparable 
acellular therapies in a developmental stage-dependent manner, both in the absence and 
presence of osteogenic cues.  The research objectives of thi thesis have been divided into 
three specific aims:   
Specific Aim I 
Establish a challenging large bone defect model in immunocompromised nude rats 
for evaluation of the abilities of human adult and fetal stem cell-based therapies to 
enhance defect healing. 
 The objectives of this aim were to establish a model of critically-sized large bone 
defects suitable for evaluation of human stem cell-based therapies and to quantitatively 
compare therapeutic potentials of tissue engineered constructs containing either adult 
bone marrow-derived or fetal amniotic fluid-derived stem cells.  Our working hypothesis 
was that treatment of large bone defects with stem cell-se ded scaffolds would enhance 
defect healing over treatment with acellular scaffolds alone, and that stem cells would 
affect healing in a developmental stage-dependent manner.  To accomplish this aim, we 
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first verified the critical size of 8 mm femoral defects in nude rats that would serve as a 
challenging test bed for xenogeneic, human stem cell-based therapies.  Next, we verified 
the in vitro osteogenic potential of human marrow-derived stem cells (hMSCs) and 
human amniotic fluid-derived stem cells (hAFS Cells) seeded on 3D porous polymer 
scaffolds when cultured in the presence of osteogenic stimuli.  Finally, we evaluated the 
in vivo therapeutic potentials of the two stem cell sources for treating large bone defects.  
The outcomes of this Aim are discussed in Chapter 3. 
Specific Aim II  
Determine stem cell biodistribution and viability throughout the large bone defect 
healing process by labeling them with an in vivo tracking agent. 
 The objectives of this aim were to first effectively label stem cells with a tracking 
agent compliant with long term in vivo imaging modalities and then to track stem cells 
delivered to segmental defects throughout the bone repair process.  Our working 
hypothesis was that a population of delivered labeled stem cells would remain viable at 
the segmental defect site to contribute to the bone healing response.  We first performed 
in vitro analyses of a novel cell tracking agent, the fluorescent quantum dot, to assess its 
internalization into both human adult and fetal stem clls as well as any potential negative 
effects on cell viability and osteogenic differentiation.  We then implanted quantum dot-
labeled stem cells seeded on porous polymer scaffolds into egmental defects and tracked 
fluorescent signals both through in vivo scans and post mortem histological analysis.   
Finally we assessed in vivo quantum dot fate after stem cell death by delivering 
devitalized stem cells to defects, evaluated quantum dot effects on defect healing, and 
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confirmed the long term associations of quantum dots with defect cell types. The 
outcomes of this Aim are described in Chapter 4. 
Specific Aim III  
Evaluate the effects of added stimulatory cues to program stem cells to differentiate 
towards an osteogenic lineage capable of enhancing segmental defect bone 
formation.   
 The main objective of this aim was to develop and test a novel viral delivery 
system for introducing osteogenic signals to human stem cells, thereby enhancing stem 
cell differentiation and promoting large bone defect repair.  Our working hypothesis was 
that delivery of osteogenic signals to segmental defect sites would enhance healing, and 
that delivery of signals through genetically modified stem cells programmed towards 
osteogenic differentiation would further enhance healing.  To accomplish this aim, we 
first tested the ability of porous polymer scaffolds coated with an adeno-associated viral 
(AAV) vector to deliver a reporter gene to cells surrounding the segmental defect site.  
Next we assessed the ability of AAV encoding the gene for the osteogenic protein bone 
morphogenetic protein 2 (BMP2) to transduce human stem cells and enhance osteogenic 
differentiation in both 2D and 3D in vitro systems.  Finally, we evaluated the segmental 
defect healing response when treated with either scAAV2.5-BMP2 coated constructs or 
scAAV2.5-BMP2 coated constructs pre-seeded with hMSCs.  Control defects were 
treated with AAV-Luciferase coated constructs or AAV-Luciferase coated constructs pre-





Large bone defects pose a common clinical challenge currntly lacking an optimal 
solution.  Bone tissue engineering strategies aim to best current therapies, and strategies 
that include cellular components may be particularly important in treating severe defects 
lacking adequate endogenous cell populations.  This work is significant because it 
established a challenging orthotopic bone defect model for human cell-based therapeutics 
and quantitatively compared a variety of stem cell-based treatments.  It evaluated efficacy 
of both adult and fetal stem cell-based tissue engineering constructs and assessed the 
effects of added osteogenic stimulatory cues on defect healing.  This work produced the 
following outcomes: 1) Established a rigorous and reproducible small animal large bone 
defect model for allogeneic or xenogeneic cell-based therapi s with quantitatively 
comparable outcome measures, 2) Displayed the therapeutic bnefits of stem cell-seeded 
constructs over acellular constructs, 3) Revealed limitations in use of quantum dots as a 
long term in vivo cell tracking agent, 4) Displayed the therapeutic potential of  novel 
method for gene therapy-based osteogenic bioactivation of scaf olds for use in both in 
vivo and in vitro gene therapy applications. 
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Chapter 2 
LITERATURE REVIEW  
Bone Introduction  
Bone Function 
Bone serves a variety of physiological functions.  Bones participate in mineral 
level homeostasis, including storage and release of calcium, phosphate, sodium, and 
magnesium to regulate ion concentrations in body fluids.  The marrow cavity in bone is 
the site of hematopoiesis, which is the formation and development of red and white blood 
cells, and it also contains a population of mesenchymal progenitor cells that can 
differentiate down a variety of cell lineages.  Bone also serves a variety of mechanical 
functions, including protecting vital organs such as the brain, spinal cord, and heart, 
supporting soft tissues attached to bone, and serving as a structural framework of levers 
on which muscles can act to cause motion (Baron 1993).  Finally, the small bones of the 
ear play an important role in hearing.   
Bone Structure 
Bone structure can be evaluated on a variety of size scales, from entire whole 
bones at the largest level down to micron-sized structual features at the ultrastructural 
level (Weiner 1998).  A bottom-up analysis of the multiple scales from smallest to largest 
presents a clear picture of the overall structure of bone. 
Ultrastructural Level: Woven and Lamellar Bone / Bone Matrix  
The ultrastructural bone level exists at a length scale of 1-10 microns and can be 
divided into woven and lamellar bone.  Woven bone is composed of randomly aligned 
collagen fibers and irregularly shaped vasculature lined with os eoblasts (Kalfas 2001).  It 
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is found primarily during embryonic development, wound repair rocesses, and in some 
disease states.  Woven bone remodels into mature lamellar bone, which features 
uniformly aligned collagen fibrils that form sheets called amellae.  Lamellar bone is 
found within healthy mature bone and is stronger than woven bone due to its organized 
collagen fiber network and thicker individual fibers.  Fibers in adjacent lamellae are 
aligned at differing angles and additional fibers bridge between them, providing strength 
under a number of loading directions.   
The bone extracellular matrix can be described as a composite material consisting 
of three phases (Recker 1992).  The mineral phase of bone is comprised mostly of 
calcium phosphate and calcium carbonate which form crystals known as hydroxyapatite 
and makes up approximately 65% of bone dry weight, contributing to bone strength and 
stiffness.  The organic phase of bone is comprised primarily of type I collagen fibers and 
makes up approximately 35% of bone dry weight, contributing to bone toughness and 
ductility. The third phase of bone is water, which makes up approximately 20% of bone 
total weight, also contributing to bone ductility.  
Apparent Bone Level: Cortical and Trabecular Bone  
 The apparent bone level exists at a length scale of 5-10 millimeters, and the bone 
structures making up whole bone can be divided into cortical and trabecular bone.  Dense 
cortical (also called compact) bone forms the internal and external tables of flat bones 
and the outer surfaces of long bone shafts.  The primary cortical bone substructures are 
osteons, which are concentric cylindrical bone formations of lamellae surrounding 
vascular channels called Haversian canals oriented along the longitudinal axes of bones.  
Transverse channels called Volkmann’s canals connect adjacent osteons, providing a 
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space for vascular connections and allowing fluid flow and mass transport to the bone’s 
outer surface (Currey 1984).  Osteocytes are bone cells that are embedded within osteons 
in small cavities called lacunae, and these cells form connections with each other by 
extending cytoplasmic cellular processes through canaliculi and forming gap junctions.  It 
is through these connections that transfer of ions and nutrie ts can occur as well as 
transmission of signals that are vital to bone remodeling.  The networks of osteons in 
long bones are contained between an inner membrane known as the endosteum that is 
adjacent to the bone’s central marrow cavity and an outer membrane known as the 
periosteum which covers the outer surface of the bone.  Both membranes provide a 
vascular supply and are hosts to osteoprogenitor cells.  Cortical bone makes up 
approximately 80% of the human body’s bone mass (Buckwalter, Glimcher et al. 1996).   
Trabecular (also called cancellous) bone exists between cortical bone surfaces and 
can typically be found at the ends of long bones and within vertebral bodies.  Trabecular 
bone consists of a network of rods and plates known as trabeculae that are joined together 
in a sponge-like network resulting in a higher surface areaper unit weight than cortical 
bone.  The network of trabecular struts or trusses act like a shock absorber and its 
orientation can vary as the bone adapts to local changes i  mechanical loads.  Marrow 
and cells occupy the pore spaces of the trabecular bone.  Trabecular bone makes up 
approximately 20% of the body’s bone mass. 
Whole Bone Level: Long, Short, Flat, and Irregular Bones  
 The whole bone level exists at a length scale of one ce timeter or longer and can 
be divided by general shape into long, short, flat, and irregular classes (Gray 1918).  
Long bones are characterized by a central shaft known as the diaphysis bordered by 
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expanded ends known as the epiphyses. The epiphyseal ends are covered with articular 
cartilage to facilitate motion within joints.  Between the two regions lie cartilaginous 
growth plates in long bone sections called the metaphyses.  Long bones have high length 
to width ratios.  The majority of bones in the limbs are long bones except for the wrist, 
ankle, and patella.  While large bones like the femur and tibia are long bones, so are small 
bones such as the metacarpals and metatarsals.  Short bones are approximately cube-
shaped, being as wide as they are long, and include the bones of th  wrist and ankle, such 
as the carpals and tarsals.  A subset of the short bones are the sesamoid bones, which are 
bones embedded in tendons that serve as spacers, moving the tendon away from the 
adjacent bone surface and providing muscles with increased leverage for motion.  
Examples are the patella and pisiform.  Flat bones ar generally thin and curved. These 
bones serve to protect the internal organs, and include most bones in the skull, the 
sternum, the scapula, and the pelvic girdle.  Irregular bones have odd shapes that do not 
fit into the other three shape categories.  The vertebrae of the spine and some facial bones 
such as the mandible are irregular. 
Key Cell Types Found In Bone: 
Osteoblasts 
Osteoblasts are mature mesenchyme-derived bone cells that contribute to the bone 
formation process through secretion of osteoid, the unmineral z d organic matrix that 
subsequently becomes mineralized after 24-74 hours.  Osteoid mineralization occurs 
through nucleation of calcium phosphate crystals followed by crystal growth and finally 
hydroxyapatite formation (Robey 1989).  Osteoblasts and osteoprogenitor cells are 
present on all nonresorptive bone surfaces, including the deep layer of the periosteum on 
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the outer bone surface and the inner endosteal surface within the medullary canal space 
(Kalfas 2001).  Osteoprogenitor differentiation to mature osteoblasts is dependent on 
expression of a number of factors, with runt-related transcription factor-2 (Runx2) and 
Osterix being two of the most important (Robling, Castillo et al. 2006), (Harada and 
Rodan 2003).  Markers of mature osteoblasts include the matrix proteins type I collagen 
and osteocalcin as well as the enzyme alkaline phosphatase.   
Osteocytes 
Osteocytes are mature osteoblasts that become trapped within secreted bone 
matrix.  Osteocytes represent the majority of bone cells.  Osteocytes maintain 
cytoplasmic connections with each other and other cellsthrough a network of cylindrical 
canaliculi (Baron 1993).  Osteocytes help to control extracellular concentrations of 
calcium and phosphorus, and they also play a role in bone remodeling under certain 
stimuli (Kalfas 2001).  Genetic markers of osteocytes include dentin matrix protein-1 and 
matrix extracellular phosphoglycoprotein (Robling, Castillo et al. 2006).  
Osteoclasts 
Osteoclasts are multinucleated cells of hematopoietic origin (mostly from the liver 
and spleen) that form through differentiation of monocyte/macrophage precursors at or 
near bone surfaces.  Osteoclasts are responsible for bone resorption through acid 
hydrolysis. Osteoclast differentiation and function are both highly regulated by receptor 
activator of nuclear factor κB ligand (RANKL), which is itself expressed by osteoblasts 
(Karsenty 2003).  Markers of mature osteoclasts include tartra e-resistant acid 
phosphatase and calcitonin receptor.   
Osteoprogenitors 
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 Bone marrow, the endosteum, and the periosteum contain a population of 
osteoprogenitor cells with the potential to differentiate into a variety of mesenchymal 
tissues such as bone, cartilage, muscle, and fat (Patterson, Kumagai et al. 2008).  These 
cells differentiate into osteoblast precursors and then into mature osteoblasts when 
directed by specific signaling stimuli such as Runx2, Osterix, o  other growth factors.   
Key Biochemical Factors Influencing Bone Formation 
Bone metabolism and development are affected by a multitude of molecules, both 
found within and attached to bone matrix and as soluble factors (Sikavitsas, Temenoff et 
al. 2001), (Allori, Sailon et al. 2008), (Wozney, Rosen et al. 1988).  Some of the more 
important matrix molecules, along with their presumed roles, include osteocalcin 
(mineralization inhibitor / bone resorber), osteonectin (nucleator for matrix 
mineralization), alkaline phosphatase (ALP – promoter of matrix crystal formation), 
fibronectin (promoter of cell attachment), thrombospondin (organizer of extracellular 
matrix components / growth factor), proteoglycans I and II (collagen fiber growth 
modulator), osteopontin (cell attachment promoter), and bone sialoprotein (cell 
attachment promoter).   
Some of the more important soluble factors include vitamin D (stimulator of both 
bone resorption and matrix mineralization), growth factors such as bone morphogenetic 
proteins (BMPs – stimulator of chondrocyte and osteoblast proliferation / osteoprogenitor 
differentiator), fibroblast growth factors (FGFs – stimulator of osteoprogenitor, 
osteoblast, and chondrocyte proliferation), insulin-like growth factors (IGFs – stimulator 
of osteoblast and chondrocyte proliferation and matrix secretion), platelet-derived growth 
factor (PDGF – stimulator of chondrocyte and osteoblast proliferation), transforming 
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growth factor-β (TGF- β – differentiator of osteoprogenitors to chondrocytes, stimulator 
of chondrocyte and osteoblast proliferation), epidermal growth factor (EGF – stimulator 
of chondrocyte proliferation), and vascular endothelial growth factor (VEGF – stimulator 
of angiogenesis through enhanced proliferation and migration of endothelial cells) 
(Carano and Filvaroff 2003), hormones such as parathyroid hormone (PTH – 
differentiator of osteoprogenitors to osteoclasts, liberator of calcium from bone matrix), 
estrogen (reducer of bone resorption by osteoclasts), dexameth sone (promoter of 
osteoprogenitors to chondrocytes and osteoblasts), thyroxine (stimulator of osteoclastic 
bone resorption), and calcitonin (inhibitor of osteoclast function), and cytokines such as 
prostaglandins (stimulator of osteoclast proliferation and osteoprogenitor differentiation 
to osteoclasts) and interleukin-1 (stimulator of proliferation of osteoclast precursors).  
Bone Development 
Bone development occurs by three processes: endochondral ossification, 
intramembraneous ossification, and appositional bone formation (Sikavitsas, Temenoff et 
al. 2001), (Kronenberg 2003).  Endochondral ossification, as occurs in long and short 
bone development and fracture healing, begins when osteoprogenitors condense, 
differentiate into chondrocytes, and secrete a cartilaginous matrix in the general pattern 
of the bone to be formed.  Chondrocytes proliferate and a periosteal layer forms in the 
diaphyseal region of the developing bone which then begins to mineralize, forming a 
primary ossification center known as a bone collar.  Chondrocytes then become 
hypertrophic, enabling them to produce proteins to enhance matrix mineralization.   Next 
chondroclasts degrade some of the matrix of the periosteum of the diaphysis and a 
vascular network begins to form along with a marrow cavity.  Osteoprogenitors invade 
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the cartilage and then differentiate into osteoblasts.  The osteoblasts proliferate and 
contribute to bone growth that increases longitudinally from the central primary 
ossification center, followed by formation of secondary ossification centers at the ends of 
the forming bone.  The bone ends grows radially rathe t an longitudinally and cartilage 
formed in the region develops into growth plates.  The calcified cartilage becomes 
mineralized by the osteoblasts, eventually forming woven bo e which later becomes 
lamellar bone.  The long bones continue to grow longitudinally as epiphyseal cartilage is 
replaced by mineralized bone on the diaphyseal bone ends (Buckwalter, Glimcher et al. 
1996).   
Flat bone formation occurs through intramembraneous ossification.  The process 
begins as groups of mesenchymal osteoprogenitors form layers nd produce a matrix 
containing blood vessels and more osteoprogenitors.  Eventually osteoprogenitors 
differentiate into osteoblasts and secrete bone matrix, fusing the layers without the initial 
presence of a cartilaginous layer.   
Radial long bone growth in the diaphysis occurs through a process called 
appositional bone formation.  In this process osteoblasts form new bone on older bone 
surfaces rather than on cartilaginous tissue.  Appositional bone formation also occurs 
during bone remodeling.  All three bone formation processes can occur simultaneously. 
Bone Homeostasis, Modeling, and Remodeling  
Bone is a dynamic tissue that must adapt to biochemical and mechanical 
environmental changes in order to adequately perform its key functions described 
previously.  In the 19th century Julius Wolff was one of the first suggest that bone 
structure adapts to changes in functional need.  In the 20th century Harold Frost expanded 
 15
upon this idea, suggesting that mechanical strain levels were responsible for changes in 
bone structure (Frost 1963).  Frost’s mechanostat theory suggests that in developed bones 
there is a homeostatic physiological strain level betwe n approximately 200 and 1500 
microstrain, and that strain levels below this threshold (such as caused by extensive 
bedrest or spaceflight) will cause bone loss, while strain levels above this threshold (such 
as caused by vigorous exercise or weight lifting) will result in additional bone formation 
(although extremely high strains will result in bone damage nd fracture). The processes 
of either enhanced bone formation or resorption are known as modeling, while the 
homeostatic process of coupled bone formation and resorption is known as bone 
remodeling (Robling, Castillo et al. 2006).   
The effectors of bone modeling are either osteoblasts which form new bone or 
osteoclasts which resorb bone, while remodeling uses a coupled combination of the two 
cell types.   In the remodeling process, hormonal or physical timuli cause osteoclasts to 
form groups called cutting cones that attach to bone surfaces through cytoskeletal 
rearrangement (Parfitt 1984).  Next osteoclasts form tight junctions with bone surfaces, 
creating a compartment into which they secrete hydrolytic enzymes that dissolve both the 
organic and inorganic components of bone matrix, resulting in shallow pits in the bone 
called Howship’s lacunae (Dee 1988).  Osteoblasts then deposit layers of osteoid in the 
pit, which are later mineralized.   
Bone modeling and remodeling are controlled by a wide variety of signaling cues.  
RANKL upregulation by signals from stromal-derived cells induces osteoclast activity by 
binding to RANK on osteoclasts.  Osteoclast activity is blocked by downregulation of 
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RANKL or by expression of osteoprotegerin, a decoy receptor that binds RANKL, thus 
preventing osteoclast activity and leading to osteoclast apoptosis.   
Bone Pathophysiology, Defects, and Repair 
Bone Pathophysiology and Defects 
Bone defects include both chronic and acute conditions.  Many chronic skeletal 
diseases are linked to imbalances in bone remodeling.  Osteoporosis, periodontal disease, 
rheumatoid arthritis, multiple myeloma, and metastatic cancer are linked to excessive 
osteoclast activity leading to excessive bone resorption (Boyle, Simonet et al. 2003), 
while other diseases such as osteopetrosis are caused by excessive osteoblast activity with 
limited resorption.  Acute conditions can be caused by tumor resection or traumatic 
injury.  Trauma can cause transverse or spiral fractu es in bone, while extreme cases can 
cause more severe bone shattering.  Large bone defects caused by severe trauma or 
osteotomy of large sections of bone are particularly challenging to repair (Werntz, Lane 
et al. 1996), as are cases of osteomyelitis, which is acute or chronic bone infection. 
Fracture Healing  
The normal long bone healing response to damage in the form of fracture consists 
of initial inflammation, followed by soft then hard fracture callus formation, and finally 
late bone remodeling (Khan, Yaszemski et al. 2008).  In the inflammatory stage, a 
hematoma develops within hours to days after injury followed by fibroblast and 
inflammatory cell invasion.  Early vascular invasion accompanies formation of 
granulation tissue along with migration of osteogenic preursors. During the second stage 
lasting from a few weeks to months a collagen matrix is formed along with osteoid 
secretion from osteoblasts, forming a soft callus around the fracture site.  If the fracture 
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site is immobilized through fixation, such as by attachment of metal plates and screws, 
the osteoid becomes increasingly mineralized forming a hard callus between bone ends 
primarily made up of woven bone.  The last repair stage occurs during a period of months 
to years as bone remodels with woven bone being gradually rep aced by organized 
lamellar bone and bone structure and strength returning to pre-damage levels (Kalfas 
2001).  
Clinical Need For Large Bone Defect Repair 
As mentioned previously, in fracture nonunions and large bone defects the normal 
fracture healing response does not occur or does so only to a limited extent, due to a 
variety of factors such as soft-tissue damage, loss of vasculature, distraction of fracture 
fragments, soft-tissue interposition, malnutrition, infection, instability, periosteal 
stripping, and systemic disease such as rheumatoid arthritis (Tseng, Lee et al. 2008).  The 
lack of a healing response creates a need for surgical interve ions, such that 
approximately one third of bone grafting procedures performed in the United States are 
for patients with nonunions or large defects (Bucholz 2002). 
Current Clinical Techniques For Treatment Of Large Bone Defects  
The current gold standard for treating large bone defects is the autograft.  
Autografts possess all of the key features contributing to bone repair: the bone donor and 
patient are the same person so there are no risks of immune rejection,  they contain live 
osteogenic cells capable of responding to signals to generat bone, they contain blood 
vessels to deliver nutrients and remove waste, and they have the properties of both 
osteoconduction (supporting bone growth into graft) and osteoinduction (producing 
signals to induce proliferation of stem cells and their differentiation to bone cells) (Tseng, 
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Lee et al. 2008).  However, autografts have many drawbacks as well, namely a lack of 
large amounts of bone available for harvesting (the predominant source is iliac crest bone 
from the pelvis), donor site morbidity as high as 10-30%, the potential for injury to 
nerves and blood vessels during harvesting, and possible infectio  or hematoma 
formation (Younger and Chapman 1989).  One alternative graft option used in place of 
autografts is processed allograft bone taken from cadavers.  While these graft materials 
do not require harvesting a patient’s own bone and are available n larger quantities than 
autografts, they have many drawbacks including a lack of live osteogenic cells, 
possibility of disease transmission, lack of porosity thus limiting vascular invasion, and 
limited remodeling and integration with host bone leading to a 25-35% failure rate due to 
nonunion and fracture, generally occurring within the first year or two after delivery 
(Berrey, Lord et al. 1990).    
Bone Tissue Engineering  
Due to the numerous problems inherent in current treatments for large bone 
defects there is a clear need for improved therapies.  Bone tissue engineers aim to fill this 
need by trying to create a graft substitute possessing the ben fits of both autograft and 
allograft without their drawbacks (Guldberg, Oest et al. 2004).  Langer and Vacanti 
described tissue engineering as the “interdisciplinary field that applies the principles of 
engineering and the life sciences toward the development of biol gical substitutes that 
restore, maintain, or improve tissue function” (Langer and Vacanti 1993).  The general 
approach to creating a tissue-engineered graft substitute is to create a construct consisting 
of some combination of osteoconductive scaffold / matrix / substrate material, osteogenic 
cells, and / or osteoinductive bioactive factors.   The scaffold serves as a template for 
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repair as well as a delivery vehicle for cells and / or bi active factors.  The bioactive 
factor generally provides cues to increase differentiation of osteoprogenitors and enhance 
mineralization. Bioactive factors are generally in the form of an osteoinductive growth 
factor or gene or other stimulatory molecule.  Cells are solely responsible as the endpoint 
effectors of bone repair because they produce the new bonematrix.  Bone tissue 
engineering therapies either rely on osteogenic responses from existing host cells at 
defect sites or feature a cell delivery component.   
Bone Defect Models 
 To evaluate potential new tissue engineering therapies for healing large bone 
defects, in vitro studies can give initial proof of concept results but in vivo models must 
ultimately be established since they better resemble the complicated biological 
environments that would occur in patients.  In vivo models should be challenging so that 
the effects of different therapies can be discriminated.  Choices for in vivo bone defect 
models include calvarial or mandibular bone defects as well as radial, ulnar, tibial, or 
femoral long bone defects.  Calvarial defects are often repaired after implantation of only 
porous scaffolds and thus are not a challenging model, likely due to the presence of many 
osteoprogenitor cells in the surrounding periosteum and an extensive vascular supply 
source in the dura mater (Guldberg, Oest et al. 2004).  Mandibular defects also frequently 
heal spontaneously, with control saline treatment leading to defect closures of 29% in one 
study (Srouji, Rachmiel et al. 2005), also likely due to extensive local periosteal 
osteoprogenitor supplies.  
 Truly challenging models of large bone defects are critically-sized, meaning that 
bone will not spontaneously regrow across the defect if it is left empty, even for extended 
 20
periods of time (Hollinger and Kleinschmidt 1990).  Large defects in the long bones 
appear to be a better representation of challenging defects than those created in flat 
bones, as defects can be made increasingly challenging by increasing the percentage of 
the long bone diaphysis that is osteotomized.  While femoral defects require some type of 
internal or external fixation device to provide defect-site tability, defects created in the 
ulna, radius, or tibia each feature a load-sharing bone (radius, ulna, or fibula) which may 
remove the need for added fixation.  However, the presenc  of the adjacent bone presents 
a periosteal surface that may host a large number of osteoprogenitors and a developed 
vascular network, and load-sharing bones allow for osteogenic stimulation of defects 
through mechanical loading (Tuominen, Jamsa et al. 2001).  
Femoral segmental bone defects likely represent the most accurate model of 
challenging large bone defects.  These bone defects are i olated from the vascular and 
osteoprogenitor supplies of adjacent load-sharing bones (except for the limited amounts 
present at the bone ends bordering the osteotomized defect), and they require fixation 
devices which generally shield them from osteogenic mechanical stimuli.  Femoral bone 
defect models have been established in a variety of animals including mice, rats, rabbits, 
and dogs (Tseng, Lee et al. 2008).  Rodent models are an attrctive option that have been 
used extensively for preliminary therapies due to a variety of factors including short 
times to reach skeletal maturity, limited housing requirements, and low costs.  The larger 
sizes of rats compared to mice allow for more manageable physiological and surgical 
techniques (Hara, Murakami et al. 2008).  
 Large bone defect models in the rat femur have been used ext nsively, although 
many of them are questionable as a critically-sized defect.  Defects of 5 mm lengths or 
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less have been used in both immunocompetent (Yasko, Lane et al. 1992), (Betz, Betz et 
al. 2006), (Lee, Shea et al. 1994), (Lin, Barrows et al. 2003) and immunocompromised 
(Jager, Degistirici et al. 2007) rats, but spontaneous healing has occurred in many of them 
(Yasko, Lane et al. 1992), (Betz, Betz et al. 2006), (Lin, Barrows et al. 2003).  Therefore 
a truly critically-sized rat femoral defect should be larger than 5 mm, and a length of 8 
mm has been used previously (Oest, Dupont et al. 2007), (Rai, Oest et al. 2007), 
(Lieberman, Le et al. 1998).   
We have previously established an 8 mm critically-sized rat femoral defect model 
in immunocompetent Sasco Sprague Dawley rats for evaluating cellular therapies 
delivered on either poly(L-lactide-co-D,L-Lactide) (PLDL) (Oest, Dupont et al. 2007) or 
poly(ε-caprolactone) / tricalcium-phosphate (PCL/TCP) (Rai, Oest et al. 2007) porous 
polymer scaffolds.  The fixation device used in the model (Figure 3.1) consists of a 
modular design in which the polysulfone bridging plate is attached to a stainless steel 
plate located on each end of the osteotomized defect rather than to the femur itself.  This 
design allows for removal of the defect-bridging polysu fone plate to be removed without 
agitation of the defect site prior to mechanical testing to evaluate restoration of bone 
function.  This mode of fixation is advantageous over that r ditionally used in rat 
femoral defects, which consists of a simple polyethylene plate that is directly affixed to 
native bone ends by pins or Kirschner wires.  The direct connection between plate and 
native bone / implanted therapeutic device can block cellular and vascular access to that 
portion of the device and also lead to ectopic bone formation along the plate (Kadiyala, 
Young et al. 1997).  Additionally, plates must generally be removed by pulling out 
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fixation pins or by sawing out the middle of the plate prior to mechanical testing, which 
can lead to destruction of any mineral network formed by the therapeutic construct.   
Our current goal of investigating cell-mediated repair of large bone defects in rats 
using xenogeneic human cells calls for use of an immunocompromised athymic nude rat 
model since these animals, which lack T-cells, are much less likely to reject implanted 
foreign cells than immunocompetent rats.  Ideally, themodel should allow for 
quantitative analysis methods assessing functional integration with native bone, including 
bone formation in the defect, vascular ingrowth, scaffold resorption, restoration of 
mechanical properties, and tracking of delivered cells.    
Scaffold / Matrix / Substrate Options: 
Scaffold / matrix / substrate biomaterials serve a variety of purposes in bone 
tissue engineering applications (Lee and Shin 2007).  Some of them include acting as a 
delivery vehicle for bioactive factors or cells and possibly releasing them at a controlled 
rate, providing structural support to bone defects, and allowing for infiltration of 
neovasculature and osteogenic cells. Materials should be ideally be biocompatible, 
noncytotoxic, and nonimmunogenic, allow for cell infiltration, adhesion and 
proliferation, be biodegradable so that they do not block formation of developing new 
bone, and have mechanical properties comparable to adjacent bone for structural integrity 
(Muschler, Lane et al. 1990).  Materials should also ideally be compatible with a variety 
of fabrication techniques and delivery methods including formation as porous scaffolds, 
microparticles, hydrogels, or nanofibrous membranes.  Further fabrication control is 
possible for some materials through microscale technologies, which allow material 
characteristics to be controlled at the micron level, b tter mimicking the features of the 
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natural bone environment in order to enhance bone repair (Khademhosseini, Langer et al. 
2006).  
Some general material choices include natural and synthetic polymers, inorganic 
materials, and their composites.  Natural polymers include collagen, fibrin, alginate, silk, 
hyaluronic acid, and chitosan (Seeherman and Wozney 2005).  Most natural polymers are 
biocompatible, biodegradable, and are easily solubilized.  Disadvantages include 
immunogenicity, poor mechanical strength, fabrication difficulties, and potential risk of 
pathogen transmission.  Since type I collagen is the most abundant protein in the bone 
extracellular matrix, many have investigated its potential in bone tissue engineering 
therapies and it is even in use in human clinical bone defect treatments (InFuse by 
Medtronic).  It can be fabricated into a variety of forms and is biocompatible, but it is 
mechanically weak and degrades rapidly in vivo, although chemical crosslinking can 
enhance strength and increase degradation times.  Fibrin has been crosslinked to form an 
adhesive gel (Arnander, Westermark et al. 2006), which could be injected into defect 
sites with or without included cells (Bensaid, Triffitt e al. 2003).  Silk has strong 
mechanical properties and is biocompatible and biodegradable (Kim, Kim et al. 2007).  
Chitosan, which is a derivative of chitin and linear polysacch ride, allows for a variety of 
formulations, including sponge, porous scaffold, and nanofiber (Jiang, Abdel-Fattah et al. 
2006).  One disadvantage of chitosan is that it is not readily degraded in normal 
physiologic fluids and requires more acidic conditions for resorption. 
Synthetic polymers are used frequently in bone tissue engineering applications 
due to the ability to tailor their properties, such as molecular weight, functional groups, 
and configurations of polymer chains, depending on desired applic tion (Lutolf and 
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Hubbell 2005).  This tailored structure allows for a much better control of degradation 
kinetics than in natural polymers (Holland and Mikos 2006).  Degradation of synthetic 
polymers generally occurs through hydrolysis and enzymatic cleavage.  Synthetic 
polymers generally possess more mechanical strength than natural polymers and pose 
less danger of immunogenicity or disease transmission (Saito, Murakami et al. 2005).  
Possible disadvantages of synthetic polymers include initiat on of an inflammatory 
response or pH decrease due to release of acidic by-products, slow clearance rates, and 
limited bioactivity.  Some of the most common synthetic polymers are made up of α-
hydroxy esters and include poly-lactic acid (PLA), poly-glyco ic acid (PGA), or their 
copolymer PLGA, poly-(ε-caprolactone) (PCL), and poly-ethylene glycol (PEG).   
Inorganic materials also provide some options for use in bone tissue engineering 
therapies.  Inorganic materials are generally stiffer than organic polymers, but they are 
also more brittle, some lack bioactivity or sufficient porosity, and degradation kinetics are 
generally longer than polymers.  Many of them contain elem nts of the inorganic matrix 
found in bone.  Materials include ceramics such as calcium phosphate cement (CPC), 
bioactive glasses, hydroxyapatite, and β-tricalcium phosphate, as well as metals such as 
titanium.  CPC is biocompatible and biodegradable as well as osteoconductive, and it can 
be directly injected into bone defects after which it hardens into a solid form (Ginebra, 
Traykova et al. 2006).  Extended growth factor release from CPC and hydroxyapatite can 
occur due to high binding affinities of some enzymes and proteins.  Titanium has high 
strength and stiffness and is inert, but it lacks bioactivity. 
Composites of organic and inorganic materials can produce improved biomaterial 
properties.  Mechanical properties of stiff but brittle inorganic materials can be improved 
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by the addition of polymers, which provide toughness and elasticity.  Additionally, due to 
differences in degration kinetics, bioactive factors contained within each composite could 
be delivered at tailored rates, thereby enhancing therapeutic effects.  
Bioactive Factor Options 
Bone metabolism and development are affected by a multitude of biochemical 
factors (Sikavitsas, Temenoff et al. 2001).  Supplemental delivery of one or more of these 
factors in bone tissue engineering therapies, generally in supraphysiological doses, can 
greatly enhance bone defect repair.  As described previously, there are a variety of 
bioactive factor choices, but in general consistent therapeutic effects have been shown 
after delivery of growth factors, especially the BMPs (Chen, Zhao et al. 2004).   
Urist was one of the first to find that demineralized bone matrix displayed 
osteoinductive properties, mostly due to the fact that it contains low levels of proteins 
which were termed BMPs (Urist 1965).  These cytokines are members of the TGF-β 
super family.  BMP signaling involves binding of this protein to a transmembrane 
receptor to initiate Smad-dependent and –independent signaling pathways that activate a 
cascade of osteogenic transcription factors, in particular Runx2 and Osterix (Bucholz 
2002).  BMPs act by promoting the migration, proliferation, a d differentiation of bone-
forming cells and their precursors such as MSCs. In addition to its role in matrix 
mineralization, BMP2 also plays a role in cartilage and skeletal connective tissue 
formation (Wozney and Rosen 1998).  There are multiple isoforms of BMP, and BMP2, 
4, and 7 are generally considered the most osteoinductive.  BMPs are sufficiently 
conserved across species so that human BMP is also effective in lower animals (Yoon 
and Boden 2002).  Extraction of beneficial amounts of BMP from bone is not very 
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practical since there is only about one or two micrograms in one kilogram of cortical 
bone, but eventually the ability to produce human BMP was realized through 
recombinant gene technology (Wozney, Rosen et al. 1988).   
Systemic growth factor administration is generally not as effective as local 
delivery due to a lack of long term growth factor stability because of their short 
biological half lives, tissue-specific growth factor activity, and potential dose-dependent 
carcigenicity (Lee and Shin 2007).  Local delivery is generally ccomplished through 
growth factor immobilization onto or within scaffolds, matrices, or gels.  Immobilization 
methods include noncovalent (physical entrapment, surface adsorption, affinity binding, 
or ionic complexation) or covalent bonding (chemical conjugation).  While local 
recombinant protein growth factor delivery is more effective than systemic delivery, 
protein half lives are still short, so effective therapeutic benefits generally require 
administration of very high doses of protein, often causing ectopic bone formation and 
having high costs. 
One alternative to delivery of large doses of recombinant BMPs to treat bone 
defects is to program cells to increase their production of these proteins by gene therapy 
techniques.  Gene therapy is the science of transferring genetic material into organisms 
for therapeutic purposes by altering cellular function or structure at the molecular level 
(Wu, Razzano et al. 2003).  More than 1000 clinical gene therapy trials (mostly Phase I 
but at least 20 Phase II) have been approved worldwide, with 2 / 3 of them in the United 
States (Ulrich-Vinther 2007).  Some experimental investigations have demonstrated that 
gene therapy methods for bone regeneration use lower doss of cell-produced growth 
factors to yield bone healing equivalent to that achieved by the administration of higher 
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doses of recombinant growth factors (Kofron and Laurencin 2006).  Successful gene 
therapy involves multiple steps including transduction (entry of desired exogenous DNA 
first into cells and then into their nuclei), transcription of the DNA into RNA, and finally 
translation as RNA sequences encode for desired protein expression (Oakes and 
Lieberman 2000).  Multiple delivery vehicles, called vectors, have been investigated for 
delivery of exogenous DNA.  Gene therapy approaches can either be in vivo, where 
vectors are delivered directly to the site of repair to t ansduce host cells, or in vitro, where 
cells are harvested from a patient or allogeneic source, expanded in culture and 
transduced by the vector, and then implanted in the patient.  In vivo methods require one 
surgical step only, but it is more difficult to guarantee ransduction of cells and there is a 
limited selection of cells to target.  In vitro methods offer better selection of cells to 
transduce, but they require two surgeries if host cells are used and are often more costly 
and labor intensive. 
Gene therapy vectors can be divided into two main groups, either nonviral or 
viral.  Nonviral vectors are generally less toxic, less immunogenic, and easier to prepare 
than viral vectors (Jang, Houchin et al. 2004).  However, theyar  also generally less 
efficient at transducing cells, with one report estimating that the efficiency of nonviral 
vectors is 10-9 that of viral vectors (Franceschi, Wang et al. 2000).  Many nonviral 
vectors also cause high cell mortality (Song, Chau et al. 2004).  One type of nonviral 
vector is the gene-activated matrix (GAM), which consist of a degradable matrix or 
scaffold containing entrapped or adsorbed expression plasmid DNA (Fang, Zhu et al. 
1996), (Jang, Bengali et al. 2006). Other nonviral vectors act to introduce naked DNA 
into cells, including lipofection, electroporation, and use of gene guns.  Due to the 
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extremely low transduction efficiencies of nonviral vectors, viral vectors currently pose 
the most potential for use in successfully treating challenging large bone defects. 
Viral vectors such as retrovirus, lentivirus, adenovirus, and adeno-associated virus 
have been used as gene therapy vectors and all have advantages and disadvantages. The 
primary concern when choosing a viral vector for bone tissue engineering gene therapies 
must be safety.  In general, bone defects are nonlethal conditions so therapies causing 
even small increases in morbidity or mortality will not be acceptable to patients or 
surgeons (Baltzer and Lieberman 2004).  This need for safety points towards use of a 
viral vector where delivered DNA remains episomal and does n t integrate into the host 
genome, becoming chromosomal DNA.  Retrovirus has been used to deliver the gene 
encoding for BMP4 to cells that healed rat segmental defects (Rose, Peng et al. 2003).  
However, retrovirus integrates chromosomally and can cause insertational mutagenesis 
leading to unpredictable protein expression, so its safety is questionable.  Lentivirus is a 
subclass of retrovirus and has similar disadvantages.  Studies using adenoviral vectors to 
transduce cells with BMPs have been used in animal bone defect models and shown some 
successes in generating new bone (Betz, Betz et al. 2006), (Lieberman, Le et al. 1998), 
(Peterson, Zhang et al. 2005).  However, adenovirus can cause an immune response due 
to it producing additional viral proteins other than those encoded for by addition of the 
transgene of interest.  These issues, along with reports of adverse effects in clinical trials 
utilizing adenoviral and retroviral vectors (Shalala 2000), suggest that other viral vectors 
may prove to be a better choice for large bone defect repair.   
The adeno-associated virus (AAV) possesses many qualities that make it an 
attractive viral vector choice, such as the absence of host inflammatory, cytotoxic, or cell-
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mediated immune responses and the abilities to transduce a broad range of cells including 
musculoskeletal cells, infect dividing and non-dividing cells, and deliver long term gene 
expression cell types that have relatively long lifetim s, such as osteocytes or muscle 
cells.  Disadvantages include a limited packaging size, difficulty in AAV production, and 
lack of long term expression in some cells (Schwarz 2000).  The lack of long term gene 
expression may actually be an advantage for application in healing large bone defects.  
Local transient expression (on the order of weeks) of a sufficient level of protein product 
such as BMP2 to initiate osteogenesis is all that is requi d (Gamradt and Lieberman 
2004) to heal most localized bone defects compared to chronic and systemic bone 
conditions such as osteoporosis which may require extended gene expression for 
successful treatment.  AAV is a non-enveloped, small (≈ 20 nm), single-stranded DNA (5 
kb of nucleotides) subclass of parvovirus that is thermostable and resistant to solvents 
and changes in pH (Coura Rdos and Nardi 2007).  Wild type AAV (wtAAV) contains 
genetic sequences encoding for the proteins Rep and Cap which are responsible for viral 
replication and encapsidation, but these sequences (along with the majority of the AAV 
genome) can be removed and replaced by a transgene sequenc  of i terest to from a 
biologically active recombinant AAV (rAAV) vector (Schwarz 2000).  Nearly 80% of all 
adults have circulating antibodies against wtAAV, however wtAAV is not known to 
cause disease in the human population (Fielding, Maurice et al. 1998).    
Cell Options 
While some bone tissue engineering therapies may rely on local host cells to 
provide an osteogenic response, treatment of challenging large bone defects is likely to 
require a cell delivery component because patients such as t e elderly, smokers, those 
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receiving chemotherapy or radiation, and those with severely damaged wound beds may 
have compromised endogenous availability of osteogenic or osteoprogenitor cells 
(Bruder 1999).  Additionally, patients in which a large volume of bone is removed or lost, 
especially from the long bones, will lose the stem cell populations located in the marrow 
space as well in the endosteum and periosteum of that bone volume. There are a wide 
variety of active cell types present within bones, but for tissue engineering therapies 
delivery of a specific population of cells may be most beneficial (Kadiyala, Young et al. 
1997).  A large number of cells may be necessary to significa tly aid the healing response 
in challenging large bone defects, therefore stem cells are an attractive candidate for 
inclusion in bone tissue engineering therapies because they can not only differentiate into 
cells of an osteogenic lineage but also extensively prolife ate to expand the cell supply 
(Song and Tuan 2004).  Stem cells can be delivered to defect sit s through direct 
injection or by seeding them on scaffolds or matrices prior to implantation.  Stem cells 
can be delivered without any modifications, or they can be pre-differentiated in culture or 
transgenically modified to express desired proteins through gene therapy techniques as 
described previously.   
Autologous stem cells may be harvested from patients withbone defects, 
expanded in culture and then implanted back into those patints as part of a tissue 
engineering therapy.  Autologous stem cells are an attractive choice because they will not 
activate an immune response in patients, but again in manychallenging bone defect cases 
there is a very limited supply of endogenous stem cells.  Therefore allogeneic stem cells 
harvested from other patients could potentially be used for treatment.  There is evidence 
to suggest that stem cells are immune-privileged cells such that allogeneic stem cells may 
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be immunologically inert enough to successfully engraft within patients (Arinzeh, Peter 
et al. 2003).  
There are a variety of stem cell choices for bone tissue engineering, with 
potentially therapeutic cell types originating from a variety of tissues and originating 
from a number of stages of development (Waese, Kandel et al. 2008).   Some options 
include adult mesenchymal stem cells (MSCS) derived from the bone marrow, adipose 
tissue, or muscle.  More developmentally primitive stem cell sources include umbilical 
cord perivascular stem cells (HUCPVC), amniotic fluid stem cells (AFS Cells), and 
embryonic stem cells (ESCs).   
A heterogeneous population of adult stem cells has been found predominantly in 
the bone marrow (Patterson, Kumagai et al. 2008) but also in adipose tissue (Zuk, Zhu et 
al. 2001) and skeletal muscle (Jankowski, Deasy et al. 2002), among other locations.  
Adipose-derived MSCs may be a particularly attractive stem cell source because of their 
relative abundance and ease of harvest of adipose tissue compared with bone marrow 
(Wall, Bernacki et al. 2007). Adult MSCs lack a single defining marker, but they share 
certain features.  MSCs adhere to tissue culture plates and have the ability to differentiate 
into musculoskeletal tissue phenotypes such as bone, cartilage, fat, and fibrous tissue, 
although some studies have suggested they have even broader differ ntiation potential 
(Patterson, Kumagai et al. 2008).  MSCs are capable of approximately 50 population 
doublings in in vitro culture (Derubeis and Cancedda 2004). MSCs are generally obtained 
through marrow aspiration of the superior iliac crest of the pelvis (Pittenger, Mackay et 
al. 1999).   
 32
In addition to adult stem cell sources, a variety of stem cells with osteogenic 
differentiation potential can be found associated with the developing embryo and fetus.  
In a recent study directly comparing human adult and fetal bone marrow-derived MSCs, 
the fetal MSCs displayed significantly higher in vivo mineral formation in rats two 
months after subcutaneous implantation on PCL-TCP scaffolds (Zhang, Teoh et al. 
2009).  Human umbilical cord perivascular cells (HUCPVCs) are pericyte-like cells from 
the umbilical cord vessels.  These mesenchymal progenitor cells proliferate extensively 
without loss of multipotent differentiation potential and can form osteoblasts, adipocytes, 
chondrocytes, myoblasts, and fibroblasts (Sarugaser, Lickorish et al. 2005).  A small 
population of multipotent fetal stem cells exists within the amniotic fluid.   (Tsai, Lee et 
al. 2004), (De Coppi, Bartsch et al. 2007).  These cells express th  membrane receptor c-
kit as well as many ESC markers including SSEA4 and Oct4, require no feeder layers for 
culture, have not formed teratomas in vivo, are capable of more than 300 population 
doublings in culture due to preservation of telomere length, and can differentiate into 
cells from all three germ layers in vitro, including osteogenic, adipogenic, myogenic, 
neurogenic, endothelial, and hepatic phenotypes (Delo, De Coppi et al. 2006).  Use of 
AFS Cells also circumvents ethical controversy associated with use of ESCs.  The 
embryonic stem cell (ESC) can differentiate into cells from all three germ layers, divide 
and renew itself for very long periods due to extended telom rase expression, and easily 
be grown in culture (Hyslop, Armstrong et al. 2005).  ESCs also have a proliferation rate 
far faster than MSCS.  However, use of ESCs is ethically ontroversial as harvesting of 
ESCs requires destruction of human embryos.  Furthermore, these cells can cause 
 33
teratomas by proliferating and differentiating uncontrollably, and they require animal-





ESTABLISHMENT OF A CHALLENGING LARGE BONE DEFECT MO DEL IN 
IMMUNOCOMPROMISED RATS FOR EVALUATION OF THE ABILIT IES OF 
HUMAN ADULT AND FETAL STEM CELLS TO ENHANCE DEFECT 
HEALING 
Chapter 3: Introduction 
 To evaluate potential new therapies for healing large bone defects, in vitro studies 
can give initial proof of concept results but in vivo models must ultimately be established 
since they better resemble the complicated biological enviro ments that would occur in 
patients.  In vivo models should be challenging so that the effects of different therapies 
can be discriminated.  Choices for in vivo bone defect models include both long bone 
segmental defects (such as in the femur or tibia) and calvari l defects.  However, 
calvarial defects are often repaired after implantation of only porous scaffolds and thus 
are not a challenging model (Guldberg, Oest et al. 2004).  Bone defect models have been 
established in a variety of animals including mice, rats, rabbits, and dogs (Tseng, Lee et 
al. 2008).  Rodent models are an attractive option that havebeen used extensively for 
preliminary therapies due to a variety of factors including short times to reach skeletal 
maturity, limited housing requirements, and low costs.  The larger sizes of rats compared 
to mice allow for more manageable physiological and surgical techniques (Hara, 
Murakami et al. 2008).  Truly challenging models of large bone defects are critically-
sized, meaning that bone will not spontaneously regrow across the defect if it is left 
empty (Hollinger and Kleinschmidt 1990).  Large bone defect models in the rat femur 
have been used extensively, although many of them are questionable as a critically-sized 
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defect.  Defects of 5 mm lengths or less have been used in both immunocompetent 
(Yasko, Lane et al. 1992), (Betz, Betz et al. 2006), (Lee, Sh a et al. 1994), (Lin, Barrows 
et al. 2003) and immunocompromised (Jager, Degistirici et al. 2007) rats, but 
spontaneous healing has occurred in many of them (Yasko, Lane et al. 1992), (Betz, Betz 
et al. 2006), (Lin, Barrows et al. 2003).  Therefore a truly critically-sized rat femoral 
defect should be larger than 5 mm, and a length of 8 mm has been used often (Oest, 
Dupont et al. 2007), (Rai, Oest et al. 2007), (Lieberman, Le et al. 1998).  We have 
previously established an 8 mm critically-sized rat femoral defect model in 
immunocompetent Sasco Sprague Dawley rats for evaluating acellular therapies 
delivered on either poly(L-lactide-co-D,L-Lactide) (PLDL) (Oest, Dupont et al. 2007) or 
poly(ε-caprolactone) / tricalcium-phosphate (PCL/TCP) (Rai, Oest et al. 2007) porous 
polymer scaffolds.   
Our current goal of investigating cell-mediated repair of large bone defects in rats 
using xenogeneic human cells calls for use of an immunocompromised athymic nude rat 
model since these animals are less likely to reject implanted foreign cells.  Ideally, the 
model should allow for quantitative analysis methods assessing functional integration 
with native bone, including bone formation in the defect, vascular ingrowth, scaffold 
resorption, restoration of mechanical properties, and tracking of delivered cells.    
Furthermore, our choice of scaffold should support cell delivery, and ideally 
include 3D porous architecture for cell attachment / proliferation, allow vascular 
invasion, be biocompatible and bioresorbable, have suitable surface chemistry and 
mechanical properties similar to the tissue at the implantation site, meet FDA approval, 
and have reproducible architecture to clinically relevant size and shape (Dawson and 
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Oreffo 2008), (Jones, Milthorpe et al. 2004).  Porous 3D honeycomb-shaped PCL 
scaffolds, designed and fabricated by fused deposition modeling t chniques, meet nearly 
all of these needs (i.e. PCL has slightly higher mechanical properties than trabecular bone 
and is resorbed through hydrolysis (Khan, Yaszemski et al. 2008)) and has shown to be 
an effective scaffold for multiple bone tissue engineering applications (Hutmacher 2000).  
PCL has been approved by the FDA for use in the human body as a drug delivery vehicle, 
suture material, or adhesion barrier. 
 As mentioned previously, stem cells are a key candidate for tissue engineering 
therapies such as repair of large bone defects due to their ability to proliferate into large 
numbers of cells as well as differentiate into musculoskeletal cells such as bone, 
cartilage, and fat cells.  Adult stem cells are present in mature adults and their purpose is 
to supply progenitors for normal tissue turnover and repair of damaged tissue.  
Friedenstein was one of the first to identify a cell population with strong osteogenic 
potential in adult bone marrow (Friedenstein 1976).  The cells would adhere to tissue 
culture dishes, form spindle-shaped cells appearing similar to fibroblasts, and proliferate 
to form colonies, so they were first called colony forming unit-fibroblasts.  The cells were 
also found to have the ability to differentiate down an osteogenic lineage when given the 
appropriate osteoinductive stimuli.  Since Friedenstein’s early work, there has been much 
research investigating adult stem cells present in bone marrow.  Adult stem cell 
populations have been found and referred to by various terms such as mesenchymal stem 
cells, bone marrow stromal cells, multipotent adult progenitor cells, connective tissue 
progenitors, and mesodermal progenitor cells (Derubeis and Cancedda 2004), (Patterson, 
Kumagai et al. 2008).   
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 Some investigators have proposed that all of these differently named cell subtypes 
are actually indistinguishable (at least at the point of initial culturing) (Lodie, Blickarz et 
al. 2002), while others claim that they are in fact distinct (Patterson, Kumagai et al. 
2008).  It is difficult to prove one viewpoint versus the other due to the fact that the adult 
stem cells lack a single definitive marker (although most display markers SH-2, 3, and 4 
and are negative for hematopoeitic markers CD34 and CD45) and there is no knowledge 
regarding their exact anatomical distribution n vivo. Although their primary location is 
thought to be in bone marrow stroma, they have also been found in other tissues such as 
trabecular bone, adipose tissue, synovium, skeletal muscle, lung, teeth, and human 
umbilical cord (Baksh, Song et al. 2004), (Caplan 2004).  Althoug  there are possibly 
some heterogeneities in these cells, they share the features of being adherent in culture 
conditions and forming colonies of spindle-shaped cells as well as having the ability to 
form one or more connective tissue phenotypes including boe, cartilage, fat, and fibrous 
tissue (Patterson, Kumagai et al. 2008).  I will refer to these stem cells as mesenchymal 
stem cells (MSCs).  Other groups have shown that under certain conditions these cells 
can be led to differentiate into neurons and epithelia in sk n, lung, liver, intestine, kidney, 
and spleen, although there is some controversy surrounding their ability to differentiate 
into cells from non-mesodermal germ layers (Baksh, Song et al. 2004).   
 Multiple studies have been performed to investigate the MSC as a therapy for 
healing bone defects.  Bruder performed some early investigations,  including use of 
autologous MSCs to heal large segmental defects in canines wh n delivered on ceramic 
carriers (Bruder, Kraus et al. 1998) and use of hMSCs to heal critically-sized defects in 
athymic nude rats when delivered on ceramic carriers (Bruder, Kurth et al. 1998).  There 
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is also evidence that MSCs may cause less of an immune response than other cells types, 
or even reduce immune responses in general, when implanted into an allogeneic recipient 
(Le Blanc and Ringden 2006).  Arinzeh showed that allogeneic MSCs delivered within 
hydroxyapatite / tricalcium phosphate carriers could heal large canine femoral bone 
defects (Arinzeh, Peter et al. 2003).  They found no immune response as assessed by 
analysis of recipient serum for production of antibodies against allogeneic cells.  
Additionally, MSCs mismatched for major histocompatibility complex antigens were 
administered intravenously into baboons receiving allogeneic skin grafts, and animals 
that received MSCs had longer graft survival compared to animals receiving no MSCs 
(Bartholomew, Sturgeon et al. 2002).  Furthermore, when allogeneic MSCs were added 
to cultures of T cells that were stimulated by allogeneic p ripheral blood lymphocytes, a 
significant and dose-dependent reduction of T-cell proliferation was evident (Di Nicola, 
Carlo-Stella et al. 2002).   Finally, co-delivery of MSCs in an allogeneic renal 
transplantation model down-regulated rat immune responses, pr erving graft function 
and prolonging animal survival, although not as well as treatment with the 
immunosuppressant cyclosporine A (Zhang, Qin et al. 2007).  However, the 
immunomodulatory effects of MSCs are still under debate, s co-delivery of MSCs in a 
rat allogeneic heart transplant model failed to reduce re ipient immune responses (Inoue, 
Popp et al. 2006).  There has also been at least one clinical trial involving harvesting of 
autologous MSCs from bone marrow aspirates, expanding them in culture, and 
implanting them into segmental defects (Quarto, Mastrogiac mo et al. 2001) .   
 Although MSCs offer great potential for use in healing lar e bone defects, they do 
have some drawbacks.  MSC numbers in vivo decrease as people age because many of 
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them differentiate during growth, development, and tissue repair throughout a lifetime 
(Caplan 2004).  Because MSCs are stem cells they can be harv sted and expanded in 
vitro, but they reach senescence and lose multilineage differentiation capability after 34-
50 population doublings in culture due to telomere shortening (Derubeis and Cancedda 
2004). For stem cell-mediated repair of large bone defects in humans, implantation of 
hundreds of millions of cells might be necessary to achieve a significant therapeutic 
effect, and achieving that number of MSCs might be difficult.  The scarcity of MSCs in 
large numbers thus prompts the search for alternative sources of multipotent cells for 
tissue engineering applications (Waese, Kandel et al. 2008). 
 The embryonic stem cell (ESC) would at first appear to be an optimal alternative 
to MSCs because it can differentiate into cells from all three germ layers, divide and 
renew itself for very long periods, and easily be grown in culture.  However, harvesting 
of ESCs requires destruction of human embryos, which is eth cally unacceptable to many.  
Furthermore, these cells can cause teratomas by proliferating and differentiating 
uncontrollably, and they require feeder layers for in vitro growth.  Therefore other fetal 
stem cell sources have been investigated that ideally would exhibit the benefits of the 
ESC while lacking its limitations.  One attractive alternative is the amniotic fluid stem 
cell.   
The process of obtaining amniotic fluid through amniocentesis has been used for 
years as a generally safe, reliable, and simple screening tool to test the fetus for a variety 
of developmental and genetic diseases (Caplan, Zwilling et al. 1968).  Approximately 10-
20 mL of amniotic fluid is harvested during the second trimester of pregnancy, and the 
fluid contains approximately 10 to 1000 heterogeneous cells per microliter of fluid (Prusa 
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and Hengstschlager 2002). Researchers have found that  subpopulations of multipotent 
progenitor cells reside within this fluid (Tsai, Lee et al. 2004), (De Coppi, Bartsch et al. 
2007).  The harvesting protocol to obtain these cells doesn t interfere with the normal 
culture process for fetal karyotyping (Tsai, Lee et al. 2004).  The multipotent cells, 
referred to as amniotic fluid stem cells (AFS Cells), make up approximately one percent 
of the heterogeneous cell population and can be isolated by positive selection for cells 
expressing the membrane receptor c-kit, which binds to the ligand stem cell factor (De 
Coppi, Bartsch et al. 2007).  These cells express many but not all of the markers of ESCs, 
require no feeder layers for culture, have not formed teratomas in vivo, are capable of 
more than 300 population doublings in culture due to preservation of telomere length 
through continued telomerase activity, and can differentiate into cells from all three germ 
layers in vitro, including osteogenic, adipogenic, myogenic, neurogenic, endothelial, and 
hepatic phenotypes (De Coppi, Bartsch et al. 2007).  Use of AFS cells also circumvents 
ethical controversy associated with use of ESCs.  They have been shown to have superior 
differentiation capacity to become hepatocytes than hMSCs in direct comparison (Zheng, 
Gao et al. 2008).  Of particular importance to bone repair, when cultured in osteogenic 
media containing dexamethasone, β-glycerol phosphate, and ascorbic acid 2-phosphate 
hAFS Cells precipitated calcium and expressed alkaline phosphatase, core binding factor 
A1, and osteocalcin, indicating differentiation into cells of an osteogenic lineage.  hAFS 
Cells have been shown to readily produce robust mineralized matrix within 3D porous 
polymer scaffolds both in vitro and ectopically in vivo (Peister, Porter et al. 2008), 
(Peister, Deutsch et al. 2009). Based on this encouraging initial data, hAFS Cells could be 
a superior stem cell than hMSCs for application to healing large bone defects.  A person’s 
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hAFS Cells could be harvested during amniocentesis, isolated in culture, and 
cryopreserved for their future use.  Additionally, if hAFS Cells are immune-privileged 
cells, as MSCs possibly are, they could theoretically be obtained from any donor.   
The purpose of this Aim was to first establish a critically-sized large bone defect 
model in immunocompromised nude rats, and then to use that model as a test bed for 
comparing the therapeutic potentials of human fetal amniotic fluid-derived and adult 
bone marrow-derived stem cells as effective bone tissue engineering treatment 
modalities.  We confirmed critical defect size, even after treatment with porous polymer 
scaffolds, establishing the validity of the model as a representation of challenging large 
bone defects.  We found that while hAFS Cell-seeded PCL scaffolds displayed 
significantly higher mineral formation than hMSC-seeded PCL scaffolds after 12 weeks 
in in vitro culture in the presence of osteogenic stimuli, there were no significant 
differences in in vivo mineral formation or torsional mechanical properties betwe n 
segmental defect femurs treated with either scaffolds seeded with stem cells from either 
source or acellular scaffolds.  However, grouping all defects treated with stem cells led to 
significantly higher in vivo defect mineral formation as well as maximum torque 
compared to treatment of defects with acellular PCL scaffolds.  The lack of significant 
differences between individual stem cell groups could be explained by a lack of sufficient 
osteogenic stimuli, which could push stem cells to differentiate down an osteogenic 
lineage and enhance defect mineral formation.  Another possible explanation could be 
that implanted stem cells do not survive long enough to reveal any differences between 




Chapter 3: Materials and Methods 
 
 
Scaffold Preparation: Poly(ε-caprolactone) (PCL) cylindrical scaffolds, 9 mm 
height, 5 mm diameter, and 85% porosity were punched fromPCL sheets (Osteopore 
International, Singapore) using dermal biopsy punches.  The scaffolds feature a 
honeycomb array of layers of interconnected struts oriented in a repeated lay-down 
pattern of 0 / 60 / 120º.  Scaffolds were sterilized by ethanol evaporation and then soaked 
in a 50 µg / mL solution of the collagen-mimetic peptide GFOGER overnight at 4° C.  
The peptide, GGYGGGPC(GPP)5GFOGER(GPP)5GPC, was synthesized by the Emory 
University Microchemical Facility (Atlanta, GA) as described previously (Reyes and 
Garcia 2003).  This peptide contains the GFOGER motif, where O refers to 
hydroxyproline. The purified peptide was lyophilized as a trifluoroacetic acid (TFA) salt. 
The peptide was reconstituted at a concentration of 10 mg/mL in a 0.1% TFA solution 
containing 0.01% sodium azide (NaN3). The stock solution was diluted the working 
concentration of 50 µg/mL in PBS.  GFOGER interacts with the α2β1 integrin on stem 
cell surfaces and can induce osteoblast differentiation and enhance matrix mineralization 
(Reyes and Garcia 2004), (Reyes, Petrie et al. 2007).   Next, scaffolds were coated with 
1.5 mg / mL type I collagen (Vitrogen 100, Cohesion Technologies, Palo Alto, CA, USA) 
through lyophilization to increase cell adhesion.  Note that scaffolds used in the 
preliminary in vivo nude rat segmental defect study establishing critical defect size were 
coated with type I collagen but not GFOGER. 
Cell Culture: hMSCs (passage 3-4) were obtained as a gift from Dr. Dawin 
Prockop at Tulane University (New Orleans, LA) and were originally isolated from bone 
marrow aspirates as described previously (Sekiya, Larson et al. 2002). Human AFS Cells 
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(p 18-19) were obtained as a gift from Dr. Anthony Atala and Dr. Shay Soker at the 
Wake Forest Institute for Regenerative Medicine (Winston-Salem, NC) and were 
originally isolated from human amniotic fluid as described previously (De Coppi, Bartsch 
et al. 2007). Cells were seeded on tissue culture plates and grown to near-confluence in 
culture media (α-MEM (Minimum Essential Medium), 16.7% fetal bovine serum 
(Atlanta Biologicals, Lawrenceville, GA), 100 units/ml penicillin / 100 µg/ml 
streptomycin / 2 mM L-glutamine [PSL] (Invitrogen, Carlsbad, CA)).  Cells were washed 
with phosphate-buffered saline (PBS, Mediatech Inc., Manassas, VA) and then 
trypsinized, centrifuged, and resuspended.   Cells were counted sing a haemocytometer. 
For the 3D in vitro stem cell source comparison study, one million hMSCs or 
hAFS Cells in 100 µL of culture media were seeded onto PCL scaffolds (n=6 / cell 
source) described above and scaffolds were incubated at 37º C / 5% CO2.  Each scaffold 
was located in one well of a 12-well tissue culture plate and was held with its long axis 
upright by a custom polymer / stainless steel stand.  One hour after seeding 4 mL of 
culture media was added to each well of the 12-well plate, covering each scaffold in its 
entirety.  Standard culture media was supplemented with 1 nM dexamethasone, 6 mM β-
glycerol phosphate, 50 µg/ml ascorbic acid 2-phosphate, and 50 ng / mL L-thyroxine 
after three days, and this osteogenic media was used throughout the rest of the 12-week 
study.  Also after three days of static culture plates w re placed on a rocker plate (The 
Belly Button, Stovall Life Science Inc., Greensboro, NC) to create dynamic culture 
conditions, which can increase mass transport throughout cons ructs and possibly lead to 
fluid shear stresses on cells that can further push stem c lls towards osteogenic 
differentiation.  Media was changed every 3-4 days. 
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For the in vivo segmental defect stem cell source comparison study, culture 
procedures and scaffold coatings were similar to those used in the 3D in vitro study 
mentioned above.  However, in the in vitro study only one donor was used per cell 
source, and in this study cells from an additional donor for each cell source were pooled 
with cells from the first donor to lessen effects of donor variability.  Additionally, 
scaffolds were loaded with either three million hMSCs or hAFS Cells (n = 14 / source) 
rather than one million cells.  Stem cell-seeded scaffolds were cultured statically for 2 
days in standard culture media prior to implantation. 
Assessment of Cell Viability: Twelve weeks after seeding cells on scaffolds as 
described above for the in vitro study (one million cells / one donor), one scaffold 
containing cells from each source was removed from culture, washed with PBS, cut in 
half longitudinally with a scalpel, and then stained with Live / Dead stain (Molecular 
Probes, Inc.) Scaffolds were incubated in 4 µM calcein-AM and 4 µM ethidium 
homodimer-1 for 45 minutes at room temperature.  The scaffolds were again rinsed with 
PBS and then images were obtained on a Zeiss LSM 510 confocal microscope (Carl 
Zeiss, Thornwood, NY).  Green fluorescence of calcein-AM was detected by using a 488-
nm Argon ion laser and a band pass 505-550 filter. Red fluorescence of ethidium 
homodimer-1 was detected by using a 543-nm Helium-Neon laser and a long pass 560 
filter.  Images were obtained at locations around the periph ry, top, bottom, and central 
cut scaffold faces.   
DNA Analysis: Three days after seeding cells as described above for the in vivo 
study (three million cells / two donors), scaffolds from each source were removed from 
culture in order to quantify amount of DNA present (n = 5 / stem cell source).  The 
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approximate mass of DNA in each diploid human cells is 6.6 pg (Otto 2005), and by 
evaluating total mass of DNA per scaffold we could estimate the actual number of cells 
loaded.  Although collagen lyophilization onto scaffolds does enhance cell attachment, 
the retention efficiency will always be less than 100%.  Scaffolds were washed with PBS 
and dried overnight in a speed vacuum (DNA SpeedVac 120, Thermo Scientific).  Next 
scaffolds were digested with Proteinase K (Worthington Biochemical, Lakewood, NJ) in 
a water bath at 55°C with intermittent vigorous vortexing, followed by DNA 
quantification using a PicoGreen assay (Quant-iT PicoGreen dsDNA Quantification Kit, 
(Molecular Probes, Eugene, OR) following the manufacturer’s protocol.  Fluorescence 
was measured using a fluorescence plate reader (PerkinElmer HTS 7000) at an excitation 
of 485-nm and emission of 535-nm.  All samples were run in triplicate.  
Surgical Technique: All surgical techniques were approved by the Georgia 
Institute of Technology Institutional Animal Care and Use Committee (protocol 
A08032).  Female immunocompromised athymic nude rats (Charles River Labs, 
Wilmington, MA), age 13 weeks, were anesthetized using isoflurane.  Using an antero-
lateral approach, bilateral incisions were made over the lengths of each femur.  Each limb 
received a custom modular fixation plate secured directly to the femur using four 
miniature screws (J.I. Morris Co, Southbridge, MA), as shown in Figure 3.1 below.  This 
novel modular composite design is used to achieve reproducible stable fixation, provide a 
window for longitudinal in vivo monitoring of 3D bone ingrowth, and allow careful 
removal of the polysulfone bridging plate from the anchoring stainless steel plates prior 
to torsional biomechanical testing of functional integration (Oest, Dupont et al. 2007), 
(Rai, Oest et al. 2007).  Bilateral full-thickness diaphyseal segmental defects, 8mm-long, 
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were created using a miniature oscillating saw and flushed with saline to remove any 
bone chips.   
For the preliminary study to establish defect critical size, a collagen-coated PCL 
scaffold was press fit into one of the defects and the contralateral defect remained empty 
(n = 2 / group).  For the study comparing stem cell sources, hMSC constructs (n = 9), 
hAFS Cell constructs (n = 9), or acellular PCL / GFOGER / lyophilized collagen I 
control scaffolds (n = 8), were press fit into defects.  Wound sites were closed with 
interrupted sutures followed by wound clip application.  Rats were given subcutaneous 
injections of 0.03 mg/kg buprenorphine every 8 hours for the first 48 hours post-surgery 
and 0.01 mg/kg buprenorphine every 8 hours for the following 24 hours f r pain relief.  




Radiograph Imaging: For both the preliminary and stem cell delivery segmental 
defect studies, qualitative bone growth into defect sites was assessed by 2D in vivo digital 
FIGURE 3.1: Critically-sized rat femoral defect, showing modular stainless steel / 
polysulfone fixation plate 
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X-rays (Faxitron MX-20 Digital, Faxitron X-ray Corp., Wheeling, IL) taken at 4, 8, and 
12 weeks post-surgery after rats were anesthetized with isoflurane. 
Microcomputed Tomography (Micro-CT) Imaging:   Micro-CT is a fast and 
non-destructive technique that can be used to characterize and measure the 3D properties 
of scaffold / tissue composites during bone growth (Jones, Milthorpe et al. 2004).  Micro-
CT systems use micro-focal spot X-ray images collected from multiple viewing 
directions to produce 3D reconstructed images of sample mat rial density in attenuating 
objects such as bone (Guldberg, Ballock et al. 2003), (Guldberg, Lin et al. 2004).   
It has previously been shown that cell-seeded scaffolds can be scanned repeatedly 
to monitor mineral formation as a function of time in culture, and that weekly scanning 
radiation doses do not significantly affect mineralized matrix formation by rat calvarial 
cells or rat MSCs (Cartmell, Huynh et al. 2004), (Porter, Lin et al. 2007), (Guldberg, 
Duvall et al. 2008). For the 3D in vitro study comparing stem cell sources, cell / scaffold 
constructs were sealed in custom sterile containers and scanned by Micro-CT (Viva-CT 
40, Scanco Medical, Bassersdorf, Switzerland).  Scaffolds were scanned after 3, 6, 9, and 
12 weeks in culture.  A 38.5 micron voxel resolution, 55-kVP voltage, and 109 µA 
current were used along with a Gaussian filter (sigma = 1.2, support = 1) to suppress 
noise, and a density threshold corresponding to 180.52 mg hydroxyapatite / cm3 was used 
to discriminate newly formed mineral from polymer scaffolds.        
For both in vivo studies, quantitative defect site mineral formation was assessed 
by in vivo CT scans at 8 and 12 weeks post-surgery.  After application of isoflurane 
anesthesia, the live rats were positioned in a custom scanning chamber to isolate the 
defects in the center of the scanning region. A 38.5 micron voxel resolution was used, 
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and after scanning a constant volume of interest (VOI) approximately 4 1/3 mm long 
centered in the middle of the defect region was chosen to ensure measurement of new 
mineral formation and avoid measuring native cortical bone e ds.  A Gaussian filter was 
used to suppress noise, and a density threshold corresponding to 272 mg hydroxyapatite / 
cm3 was used to discriminate bone from soft tissues and polymer.  For the cell delivery 
study, post mortem ex vivo CT scans were performed as well.  Rats were sacrificed aft r 
12 weeks and femurs were carefully excised along with surrounding soft tissue, wrapped 
in PBS-soaked gauze, and frozen at -20ºC until scanning.  At the time of post mortem 
scans, femurs were thawed in PBS, placed in 15 mL microcentrifuge tubes filled with 
PBS, and then scanned by Micro-CT.  A 21 micron voxel resolution was used, and after 
scanning a constant volume of interest (VOI) approximately 6 1/3 mm long centered in 
the middle of the defect region was chosen to ensure measur ment of new bone formation 
and avoid measuring native cortical bone ends.  A larger VOI was used during post 
mortem scans because explanted femurs could be aligned cocentrically with the center 
of the bore of the of the CT scanning chamber, whereas during in vivo scans full 
alignment with the CT scanner was not possible due to limitations imposed by the 
geometry of the live rat within the scanning chamber.  A Gaussi n filter was used to 
suppress noise, and a density threshold corresponding to 272 mg hydroxyapatite / cm3 
was used to discriminate bone from soft tissues and polymer.  Additionally, explanted 
naïve femurs from both 25 week old nude rats as well as 25 week old immunocompetent 
Sasco Sprague Dawley rats (Charles River Labs) (n = 6 / rat type) were wrapped in PBS-
soaked gauze and then frozen until Micro-CT imaging using the same settings as the post 
mortem segmental defect scans described above . 
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Biomechanical Testing: Femurs from the cell delivery segmental defect study 
and whole naïve femurs were biomechanically tested to failure in torsion.  Immediately 
following post mortem Micro-CT imaging, defect femurs were carefully cleaned of 
remaining soft tissue in preparation for torsional testing.  Bone ends were potted in 
custom mounting blocks that contained reservoirs of heated Wood’s Metal (Alfa Aesar, 
Ward Hill, MA), an alloy that melts at low temperatures and quickly solidifies after 
potting of bone ends.   The mounting blocks were then loaded into custom holding 
brackets attached to an ELF 3200 Electroforce torsion testing ystem (Bose EnduraTEC 
Corporation, Minnetonka, MN) fitted with a 2 Nm torsional load cell.  Next the 
polysulfone bridging plate, which had shielded defects from loads and damage, was 
removed by unscrewing the four screws attaching it to the s ainless steel plates, each of 
which were screwed into to the native femoral bone on either side of the defect site 
(Figure 3.2).  Finally a rotation-controlled torsional load was applied to the femur at a 
rate of 3 degrees / second and rotation angle, maximum torque, and torsional stiffness 
were recorded through 90 degrees rotation to avoid analysis of torque generated due to 





 Data Analysis: Data were analyzed using GraphPad Prism 5 software (GraphPad 
Software, Inc., La Jolla, CA).  Analyses comparing three or more groups were analyzed 
using ANOVA with Tukey post hoc analyses for pairwise comparisons.  Analyses 
comparing two groups were analyzed using unpaired t-tests.  Whenever required, the raw 
data was transformed using a natural logarithmic transformation to make the data normal 
and the variance independent of the mean (Kutner 2005).  For the in vivo cell delivery 
segmental defect study, no significant differences existd between hMSC or hAFS Cell 
treatment, so the two groups were combined into one cellular treatment group.  Data are 
presented as mean ± standard error of mean (SEM).  A p-value < 0.05 was considered 
statistically significant. 
FIGURE 3.2: Segmental defect femur loaded in ELF3200 torsion testing system 
both before (left) and after (right) removal of polysulfone bridging plate.  
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Chapter 3: Results 
Comparison of Female Age-Matched Immunocompetent Sasco Sprague 
Dawley and Immunocompromised Nude Rats: The size of female 
immunocompromised nude rats used during segmental defect studies was significantly 
lower than that of age-matched immunocompetent Sasco Sprague Dawley rats used 
previously in the same model, as assessed by comparison of post-segmental defect 
surgery weights (Figure 3.3A).  The geometry of the femurs from both rat strains varied 
as well, with the proximal ends of nude rat femurs flaring out to a point, creating a 
teardrop-shaped cross section, compared to the nearly ovular cross sections of Sprague 
Dawley femurs (Figure 3.3B).  Although the femur geometry varied between strains, 
there were no significant differences in central diaphysis mineral volumes (Figure 3.3C) 
or maximum torques to failure (Figure 3.3D), however torsional stiffness was 
significantly lower in nude rats (Figure 3.3E), possibly due to the differences in cross 
sectional geometry of the femurs or differences in boe material properties between 





Confirmation of Critical Size of Segmental Defects in Nude Rats: Negligible 
bone formation occurred in the empty defects throughout the 12 week period, and even 
defects that received PCL/Col-I scaffolds did not display bony bridging (Figure 3.4), 
indicating that the model does represent a critically-sized defect.  There was no evidence 
of impaired health displayed during the study even after repeated handling / anesthesia 
application during radiograph and Micro-CT imaging.   
FIGURE 3.3: Comparison of relevant features of immunocompetent Sasco Sprague 
Dawley rats and immunocompromised nude rats.  A) Weight of rats taken after 
segmental defect surgery.  SSD: n = 25, nude: n = 22.  Weights for each rat strain 
were pooled from two different studies to account for variability between litters.  B) 
Comparison of geometries of femurs as assessed by Micro-CT, including transverse 
cross sections from proximal ends of evaluated diaphyseal VOIs.  C) Quantified bone 
volumes of measured diaphyseal VOIs.  D) Comparison of biomechanical properties 




3D In Vitro Comparison of Mineralization Capabilities of Human Fetal and 
Adult Stem Cell Sources: Mineral volume throughout the scaffolds significantly 
increased during the course of the study for both cell sources (Figure 3.5 A,B), and at the 
study endpoint the construct mineral volume was significantly higher within scaffolds 
that received hAFS Cells compared to those that received hMSCs. For both cell sources, 
live cells were found along the scaffold periphery, top, bottom, and occupying the central 
pore spaces of the scaffolds at the 12 weeks post-seeding time point (Figure 3.5A).  After 
12 weeks in vitro culture the vast majority of cells remained viable.  
FIGURE 3.4: Week 12 time point 2D radiographic and 3D Micro-CT images of 
defects receiving either no treatment (A, B) or treatment with PCL scaffold containing 
lyophilized col I (C, D).  Micro-CT images are shown proximal end-down, distal end-
up.  E) Geometry of PCL scaffold, showing magnified view of collagen lyophilized 




FIGURE 3.5: In vitro mineralization of 3D PCL scaffolds seeded with either MSCs 
or hAFS Cells.  A) Representative mineral formation as assessed by Micro-CT along 
with Live / Dead images showing viable green cells in the scaffold pore spaces at 
the 12 week time point. B) Quantitative comparison of bone volume in scaffolds.  n 
= 6 / group.  *, + both indicate p < 0.05. 
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 In Vivo Comparison of Human Fetal and Adult Stem Cell-Mediated 
Segmental Defect Healing: After 8 weeks post-surgery, bone bridged 0 / 8 defects that 
received scaffold only, 4 / 9 defects that received scaffold seeded with hMSCs, and 1 / 9 
defects that received scaffold seeded with hAFS Cells, as assessed by double-blind 
evaluations of 2D radiographs (Figure 3.6).  No further bridging occurred by week 12.   
 
 
FIGURE 3.6: Radiograph (above) and Micro-CT (below) images of mineral formation 
in segmental defects treated with PCL scaffolds or PCL scaffolds seeded with three 
million hMSCs or hAFS Cells. Micro-CT images shown arefrom in vivo scans taken 
at the 12 week post-surgery time point.  Samples chosen represent the maximum 
mineral formation for each treatment group as assessed by Micro-CT quantification. 
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 Micro-CT quantification of bone volume showed no stati ically significant 
differences between any group (Figure 3.7A), although the average bone volume and 
standard error for each group from in vivo scans at the twelve week time point were as 
follows: scaffold only – 9.30 ± 2.12 mm3, scaffold + hMSCs – 29.66 ± 10.31 mm3, and 
scaffold + hAFS Cells – 21.76 ± 10.00 mm3.  There were also no significant differences 
in mechanical properties between any groups (Figure 3.7B).  The in vitro DNA assay 
performed prior to implantation showed no significant differences in DNA content per 
scaffold between the two cell sources, indicating that implanted constructs initially 
contained similar cell numbers (Figure 3.7C).   
 
 
FIGURE 3.7: Quantitative comparison of acellular and cellular segmental defect 
treatments.  A) In vivo and post mortem mineral formation within defect sites. B) 
Biomechanical properties of femurs tested to failure in torsion. C) DNA masses per 
scaffold. A-B: n = 9 / each cellular group, n = 8 scaffold group.  C: n = 5 / group 
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 Although the average values for defect mineral volume and mechanical properties 
were higher for each stem cell-treated group compared to the acellular scaffold-treated 
group, significant differences were not found due to high variability.  To assess the 
effects of adding a cellular component for a larger sample size, the two cell treatment 
groups were combined and compared to treatment with acellular scaffold alone.  The 
combined cellular group displayed significantly higher in vivo bone volume as well as 
maximum torque compared to the acellular group (Figure 3.8 A,B).   
 
 
FIGURE 3.8: Quantitative comparison of acellular and pooled stem cell segmental 
defect treatments.  A) In vivo mineral formation within defects.  B) Biomechanical 
properties of femurs tested to failure in torsion.  Pooled stem cell treatments had 
significantly higher in vivo bone volume and post mortem maximum torque compared 
to acellular scaffold treatment.  n = 18 cellular, n =8 acellular.  * p < 0.05; #  p = 0.06 
 58
 
Chapter 3: Discussion 
 
 Cellular activity is a vital component of the large bone defect healing process. In 
this study, a critically-sized femoral defect model was established in nude rats for 
evaluating human stem cell-based bone tissue engineering therapies.  Delivery of stem 
cells on a porous polymer scaffold to bone defect sites led to an increase in bone 
formation and mechanical properties compared to defects reiving scaffold alone. No 
significant differences in defect bone volume or femoral mechanical properties were 
observed between adult or fetal stem cell sources.  Although stem cell delivery 
significantly enhanced bone ingrowth and biomechanical properties, consistent bone 
bridging was not observed, with 4 / 9 hMSC scaffold-treated defects bridging and only 1 / 
9 hAFS Cell scaffold-treated defects bridging.  Lack of bony u ions was likely due to the 
challenging nature of the 8 mm defect model, which is larger than the standard critical 
size required for nonunion in untreated controls.  Other investigators have used rat 
femoral defects of 5 mm length or less in both immunocompetent (Lee, Shea et al. 1994), 
(Lin, Barrows et al. 2003) and immunocompromised (Jager, Degistirici et al. 2007) rats.  
The 8 mm femoral defect may be especially challenging in 13-week old nude rats 
compared to other age-matched rat strains such as the immunocompetent Sasco Sprague 
Dawley rat.  We have consistently observed that female nude rats are smaller than age-
matched female Sasco Sprague Dawley rats through multiple segmental defect studies, 
which was quantitatively confirmed by comparison of rat post-surgery weights as shown 
in Figure 3.3.  As rat femur length tends to scale with weight (Hammett 1925), the 8 mm 
defect may represent a larger percentage of total femur length in the smaller nude rats 
than in the larger Sasco Sprague Dawley rats.   
 59
Another reason for the lack of significant differences in defect repair between 
individual stem cell treatment groups and the acellular scffold treatment group may be 
the presence of a sufficiently large host MSC and osteoprogenitor population to 
contribute to partial repair of defects in the acellular group.  As mentioned, bone tissue 
engineering therapies including a cellular component may be especially important for 
treating patients with diminished bone repair capabilities, such as the sick or elderly, due 
to a lack of endogenous cell supplies.  In order to better valuate the potential of stem 
cells as a therapeutic agent for those patients, it may be necessary to modify our model by 
using older nude rats or nude rats with disease conditions, such as nude rats with diabetes 
induced by the administration of streptozotocin (Kwon, Gao et al. 2008).  However, the 
13-week-old healthy female nude rat defect model used in these experiments represents a 
more practical large bone defect model which still serves as a valid and reproducible test 
bed for comparing xenogeneic human stem cell therapies.  Older rats could have varying 
health problems associated with the aging process and younger rats could have varying 
responses to disease-initiating treatments, both of which would likely increase the 
variability between animals and mask the effects of stem cell-based therapies.  The 
current model also allows for a more direct comparison to results from our studies 
treating 13-week-old healthy female Sasco Sprague Dawley rat defects with acellular 
therapies than if older or diseased rats were used.   
For cell-mediated repair of challenging defects, its may also be necessary to co-
delivery programming cues that direct delivered stem cells to differentiate down an 
osteogenic lineage.  Co-delivered osteogenic signals may be particularly important for 
pluripotent fetal AFS Cells, which are possibly more primitive cells than the more 
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specialized multipotent adult MSCs.  In 3D in vitro culture with osteogenic stimuli the 
hAFS Cells produced significantly more bone than the hMSCs through 12 weeks, 
possibly indicating that with added cues the hAFS Cells could produce more mineral than 
the hMSCs in vivo as well. 
Finally, there is the possibility that delivered human cells may have interacted in a 
detrimental manner with host cells.  Assuming that each human cell contains 6.6 
picograms of DNA (Otto 2005), then hMSC scaffolds on averg  delivered about 2.5 
million cells and the hAFS Cell scaffolds delivered about 1.9 million cells, based upon 
DNA levels measured by DNA assay.  Introduction of this number of xenogeneic cells 
may have elicited some level of immune response from nude rats, limiting their 
therapeutic effect.  While nude rats are T cell-deficient, their immune systems still have 
other lymphocytes such as natural killer cells and B cells. However, it is unlikely that 
delivered human stem cells would elicit an immune response, a  multiple groups have 
reported that MSCs may be immune-privileged, as discussed in the chapter introduction.  
Second, it is possible that delivered human stem cells may have deterred the endogenous 
cell response, either from host osteoprogenitors or osteogenic cells.  During the normal 
bone repair process host stem cells would occupy the injury site and differentiate into 
bone forming cells, but in this study the defects are alrady occupied by delivered cells, 
possibly limiting the host cellular response. 
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Chapter 4 
EVALUATION OF QUANTUM DOTS AS A HUMAN STEM CELL TRA CKING 
AGENT DURING LARGE BONE DEFECT REPAIR  
Chapter 4: Introduction  
 
Delivery of stem cells after bone injury, especially challenging injuries such as 
fracture nonunions or massive large bone defects, is a potential alternative to the large 
number of bone grafting operations performed annually (Song and Tuan 2004), (Jaiswal, 
Haynesworth et al. 1997), (Bucholz 2002).  In our model, deliverd stem cells should be 
able to be tracked using in vivo and ex vivo techniques to assess their location and 
viability during segmental defect repair.  Tracking implanted cells is important for 
understanding the relative contributions to the regenerated tissues and organs from 
delivered cells versus host cells (Bucholz 2002), (Shah, Clark et al. 2007).   Frangioni 
and Hajjar have suggested that an ideal agent for tracking stem cells should be 
biocompatible, safe, nontoxic, not require any genetic modification of the stem cell, 
permit single-cell detection at any anatomic location, allow quantification of cell number, 
have minimal or no dilution with cell number, have mini al or no transfer to non-stem 
cells, permit noninvasive imaging in the living subject over months to years, and require 
no injection of contrast agent for visualization (Frangio i and Hajjar 2004).  Additionally, 
in vivo imaging of specific tissues can be difficult due to non-specific light absorbance 
and scattering by other tissues leading to their autofluorescence.  However, 
autofluorescence is much lower in the near-infrared wavelengths from 700-1000 nm 
because the major chromophores in mammals, hemoglobin and w ter, have local minima 
in absorption in this range (Lim, Kim et al. 2003), (Smith, Duan et al. 2008). 
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A fairly new cell tracking modality, the quantum dot, has emerged recently as one 
option that features many of the desired traits mentioned above.   Quantum dots (QDs) 
are fluorescent nanometer-scale semiconductor crystals composed of group II-VI or II-V 
elements.  They have advantages over other fluorescent markers such as organic dyes and 
fluorescent proteins, including wide excitation spectrums (excitation by a large range of 
wavelengths of light), narrow emission spectrums (allowing for multiple populations of 
different cells to be tracked by loading QDs emitting multiple colors), photostability, and 
long fluorescence decay lifetimes (Jamieson, Bakhshi et al. 2007).  QDs are stable and 
can undergo repeated cycles of excitation and fluorescence mission for hours with a 
high level of brightness (10-20 times higher than fluorescent proteins) and limited 
photobleaching (Alivisatos 1996).  Quantum dots used in cell tracking applications are 
generally composed of a cadmium selenide core and a biologically inert zinc sulfide shell 
(CdSe/ZnS), and are also often coated with additional materials to aid in cell 
internalization since raw QDs are generally membrane impermeant (Jaiswal, Goldman et 
al. 2004).  The coatings generally consist of peptides or pr teins that increase QD 
solubility and serve as ligands for integrin binding on cell surfaces prior to QD 
internalization to endosomes in the cytoplasm.  QDs generally do not enter the cell 
nucleus as their diameters (approximately 20 nm) are much bigger than nuclear pore sizes 
(5 nm) (Shah, Clark et al. 2007).  When QD-loaded cells divide their QD contents are 
likely asymmetrically divided between daughter cells leading to a loss in concentration 
per cell.  One downside to this particular type of QD is the possible release of toxic 
cadmium from the core, but the ZnS shell helps to stabilize the core and reduces 
immunogenicity.  Another potential downside is the possibility of QD transfer from 
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originally loaded cells to neighboring cells, which could defeat the purpose of labeling 
delivered cells to distinguish them from host cells.  However, experiments by Rosen have 
not shown this to be the case (Rosen, Kelly et al. 2007).   In vitro, QD-loaded human 
mesenchymal stem cells (hMSCs) were cocultured with adult cardiac myocytes 
expressing green fluorescent protein (GFP), and no evidence was found of QDs in GFP-
expressing cells.  Furthermore, the lysates of QD-loaded hMSCs killed by mechanical 
disruption were introduced to cardiac myocyte cultures and there was still no evidence of 
QD uptake by myocytes. In vivo, they injected 100,000 QD-loaded hMSCs that were 
mechanically disrupted to cause cell lysis into the rat ven ricle and sacrificed the animals 
either 1 hour or 1 week later.  They did not observe QDs in any cell type in the hearts.  
However, they did find that QDs were removed from the circulation to organs of the 
reticuloendothelial system (RES - spleen, liver, lymph nodes), which generally occurs 
within hours after direct injection of QDs or QD-loaded cells (Ballou, Lagerholm et al. 
2004), (Akerman, Chan et al. 2002), (Hoshino, Hanaki et al. 2004), (Fischer, Liu et al. 
2006).  Another study found that when cells co-labeled with QDs and cell tracker dye 
were injected intravenously into mice, there were no cells found without both markers 
five hours later, indicating that no QDs left their original cells to go into other cells and 
that any cells that died had their QDs cleared from the circulation (Voura, Jaiswal et al. 
2004).   
The majority of in vitro studies using human mesenchymal stem cells loaded with 
QDs have demonstrated highly efficient internalization into cells and long term 
fluorescent tracking of QD-loaded cells, with no significant effects on cell viability or 
proliferation and differentiation capabilities when cells were loaded with low 
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concentrations of QDs (Shah, Clark et al. 2007), (Seleverstov, Zabirnyk et al. 2006), 
(Muller-Borer, Collins et al. 2007), (Rosen, Kelly et al. 2007).  However, one study 
reported decreased osteogenic differentiation of QD-loaded hMSCs, showing that they 
had decreased osteopontin and osteocalcin (markers of osteogenesis) expression 
compared to QD-free hMSCs, although both groups showed similar alkaline phosphatase 
expression and there were no effects on proliferation (Hsieh, Wang et al. 2006).  One 
reason for these results might be that they used immortalized hMSCs that may lack 
certain matrix markers.    
  In vivo, QD-labeled hMSCs seeded on porcine urinary bladder and delivered to 
canine hearts showed fluorescence in histological sections aken through 8 weeks of 
study (Rosen, Kelly et al. 2007).  Injection of QDs into tail veins of mice led to 
accumulation of QDs in RES organs, which displayed fluorescence for at least four 
months.  Neither macroscopic nor microscopic analysis revealed signs of localized 
necrosis in these organs (Ballou, Lagerholm et al. 2004).   Additionally, QD-labeled 
tumor cells were intravenously injected into mice, and 40 days later there were no 
apparent detrimental effects on physiology of the host anim ls, QD-loaded cell survival, 
or their ability to engraft into native tissue to form tumors (Voura, Jaiswal et al. 2004).  
Finally, in vivo imaging of fluorescence from QD-loaded cells has been observed in 
mouse capillaries hundreds of microns below the skin after intravenous injection (Larson, 
Zipfel et al. 2003).  
The purpose of this Aim was to label and track human stem c lls used in 
treatment of large segmental bone defects to assess th ir biodistribution and viability 
during the bone repair process.  Based on the above background, we chose quantum dots 
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as our cell tracking agent.  We first optimized the quantm dot labeling configuration as 
assessed by in vitro fluorescence emission by comparing multiple concentrations a d 
types of quantum dots as well as varying quantum dot incubation times.   We also found 
that low concentration QD-labeling of stem cells does not affect in vitro stem cell 
viability or osteogenic differentiation capacity.  However, segmental defect experiments 
revealed that quantum dot labeling may not be an effective long term in vivo stem cell 
tracking modality, as quantum dots were released from deliver d stem cells and 
internalized by host cells, creating false positive signals.  Furthermore, defects treated 
with scaffolds seeded with QD-loaded hMSCs displayed less robust healing than defects 
treated by scaffolds seeded with QD-free hMSCs.   
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Chapter 4: Materials and Methods 
 
Stem Cell Labeling with Quantum Dots: In Vitro Preliminary Experiment I: 
Rat MSCs (rMSCs, p3) were isolated from long bone marrow aspirates as described 
previously (Hofstetter, Schwarz et al. 2002).   20,000 rMSCs were seeded in each well of 
8-well Lab-Tek chambered cover glass plates in 300 µL of culture media (α-MEM, 
16.7% FBS, antibiotics), allowed to adhere overnight, and then loaded with either 
QTracker 800 quantum dots or QDot ITK 800 quantum dots as directed by the 
manufacturer’s protocol (Invitrogen Corporation, Carlsbad, CA).  Qtracker QDs have a 
positive surface charge through an amino-PEGylation surface coating and QDot ITK 
QDs have a negative surface charge through carboxyl group surface co ting.  Both types 
of QD exhibit peak fluorescence emission at a wavelength of 800 nm, which is an 
attractive feature for in vivo imaging because the two major chromophores responsible 
for animal autofluorescence, hemoglobin and water, display minimal fluorescence 
emission at these high wavelengths.  QDs were loaded at concentrations of 5, 10, or 20 
nM, with 10 nM being the manufacturer’s standard recommendation.  Cells were 
incubated with QDs for either one hour or overnight (18 hours), washed with PBS, fixed 
with formalin, and then washed with PBS again prior to imaging.  Additionally, some of 
the wells incubated in 10 nM QDs were stained for five minutes with 5 ng / mL DAPI 
nuclear stain.   
Stem Cell Labeling with Quantum Dots: In Vitro Preliminary Experiment II: 
rMSCs, hMSCs, or hAFS Cells seeded on Lab-Tek 8-well plates w re loaded with 
quantum dots as described above, but at concentrations of 0, 10, 15, and 20 nM, and all 
were incubated for 18 hours.  All wells were fixed and stained with 5 ng / mL DAPI 
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nuclear stain.  Additionally, cells in other 8-well plates were loaded with QDs in the same 
manner but were not fixed or stained with DAPI; instead they were washed with PBS and 
then stained with Live / Dead stain (Molecular Probes, Inc.) for 45 minutes to assess cell 
viability.    
Stem Cell Labeling with Quantum Dots: In Vitro Effect on Osteogenic 
Differentiation: To assess quantum dot effects on osteogenic differentiatio , 1,000 
hMSCs were seeded per well of tissue culture 6-well plates nd grown to confluence.  0.5 
mL of 5 nM QTracker QDs was then added to half of the wells for 18 hours while the 
other wells received 0.5 mL of culture media.  Next wells were aspirated and 5 mL of 
culture media supplemented with osteogenic factors (1 nM dexam thasone, 6 mM β-
glycerol phosphate, 50 µg/ml ascorbic acid 2-phosphate, and 50 ng / mL L-thyroxine) 
was added.  Plates were cultured dynamically for three wks in osteogenic media with 
media changes twice weekly and then a Von Kossa assay was performed to assess 
mineral formation.   
Stem Cell Labeling with Quantum Dots: In Vivo I – Preliminary Study: Three 
million hMSCs or hAFS Cells, each from two different donors, were seeded on 15 cm 
diameter Tissue culture polystyrene dishes and incubated ov rnight at 37º C / 5% CO2 in 
20 mL culture media (α-MEM, 16.7% FBS, PSL).  Cells were then incubated in a 5 nM 
solution of QTracker 800 quantum dots in 5 mL culture media for 18 hours and then 
trypsinized and counted using a haemocytometer.  Three million QD-labeled hMSCs or 
QD-labeled hAFS Cells in 100 µL of culture media were seeded onto PCL scaffolds 
previously coated with GFOGER peptide and lyophilized type I collagen.  4 mL culture 
media was added after one hour and scaffolds were cultured in 12-well plates as 
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described in Chapter 3.  Cells were allowed to adhere to and spread throughout the 
scaffolds in vitro for 24 hours prior to implanting them in rat femoral defects.   
Stem Cell Labeling with Quantum Dots: In Vivo II – Live Versus Devitalized 
Cell Study: Three million hMSCs were seeded on 15 cm diameter Tissue culture 
polystyrene dishes while three million human embryonic kidney 293 (HEK) cells (p 34, 
purchased from ATCC (American Type Culture Collection, Manassas, VA)) were seeded 
on T-150 flasks and incubated overnight in 20 mL media (hMSCs: α-MEM, 16.7% FBS, 
PSL; HEK cells: DMEM, 10% FBS, PSL).  HEK cells were used as a live non-stem cell 
control because, unlike stem cells, these cells have not been shown to possess an ability 
to home to injury sites.  Cells were then incubated at 37º C / 5% CO2 in a 5 nM solution 
of QTracker 800 quantum dots in 5 mL culture media for 18 hours and then trypsinized 
and counted using a haemocytometer.  Either three million (hMSCs only) or six million 
(hMSCs and HEK cells) QD-labeled cells in 100 µL of culture media were seeded onto 
PCL / GFOGER / Col I scaffolds and cultured as described above prior to implantation.  
Some QD-labeled hMSC constructs were exposed to devitalizing freeze-thaw cycles after 
24 hours culture consisting of three repetitions of freezing at -80ºC for 30 minutes 
followed by thawing at 37ºC for 30 minutes in a water bath.   The cells were devitalized 
to eliminate the possibility of stem cell migration from the defect site. 
Fluorescence Microscopy: Fluorescent images of QD-loaded cells in 8-well Lab-
Tek plates as well as in histological cryosection slide from in vivo studies were obtained 
using a Zeiss Axio Observer inverted microscope (Carl Zeiss Inc., Oberkoben, Germany) 
equipped with a specialized Qdot 800 filter set (Chroma 32021, Chroma Technology,  
Rockingham, VT).   
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IVIS Fluorescence Imaging: Macroscopic images of quantum dot fluorescence 
in 8-well plates were obtained using an IVIS Lumina fluorescent / bioluminescent 
imaging system (Caliper LifeSciences, Hopkinton, MA) capable of quantifying 
fluorescence emission levels.  Images were taken with 60 second exposure time, small 
binning, FStop level 2, 745 nm excitation, 800 nm emission, and field of view D (image 
size 12.5 cm x 12.5 cm) settings.    
For in vivo fluorescence imaging, in the preliminary in vivo study immediately 
after surgery rats were transported to the IVIS imaging system for in vivo fluorescence 
imaging.  The system features an isoflurane gas inlet to keep rats anesthetized during 
imaging.  IVIS imaging was repeated once each week for the duration of the 12-week 
study, using consistent settings of medium binning, FStop of 1, 13 second excitation 
time, 710 nm excitation, 800 nm emission, and field of view D.  For the live versus 
devitalized cell in vivo study, scans were performed immediately post-surgery and the  
after 10, 20, 40, 60, and 80 days using the same settings as in the preliminary study. 
Images were taken of the dorsal view as well as both the left and right sides.  
Fluorescence count values were measured using a uniform circular egion of interest 
applied at hindlimb defect sites.   
Surgical Technique: Femoral segmental defects were created in rat femora as 
described in Chapter 3.  In both of the in vivo quantum dot studies, all rats were 
implanted with scaffolds containing QD-labeled cells in one hindlimb defect and 
acellular scaffolds only in the contralateral defect.  In the preliminary QD study two rats 
were treated with hMSCs and two rats with hAFS Cells.  In the QD study comparing live 
and devitalized cells, 10 rats were treated with scaffolds containing QD-loaded live 
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hMSCs (n = 5 three million cells / n = 5 six million cells), 10 rats were treated with 
scaffolds containing QD-loaded devitalized hMSCs (n = 5 three million  cells / n = 5 six 
million cells), and two rats were treated with six million QD-loaded live HEK cells.  One 
rat treated with QD-loaded hMSCs in the preliminary QD study failed to recover due to 
misplacement of the internal fixation plate, leading to its euthanization after 4 days. 
Radiograph / Micro-CT Imaging and Biomechanical Testing: Rats in the 
study comparing live and devitalized QD-loaded stem cells were scanned by 2D 
radiographs at 4, 8, and 12 weeks post-surgery and 3D in vivo Micro-CT scans at 8 and 
12 weeks post-surgery as described in Chapter 3 (n = 9 live hMSC-loaded animals, n = 9 
devitalized hMSC-loaded animals, n = 1 HEK cell-loaded animal).  Additionally post 
mortem Micro-CT scans were performed on the same animals with a higher density 
threshold corresponding to 385 mg HA/cm3 to account for denser and more mature bone 
than in the earlier in vivo scans, and because there is not as much extraneous tiss e
present to absorb photons in explanted femurs compared to in vivo limbs.  Femurs from 
the same animals were biomechanically tested in torsion as described previously.  
Histological Cryosection Preparation and Imaging: All rats from the 
preliminary QD study were sacrificed 12 weeks after surgery and had their femurs, 
kidneys, and organs of the reticuloendothelial system (spleen, liver, lymph nodes) 
harvested.  Femurs were decalcified in Cal-Ex II solution (Fisher Scientific), and then all 
tissues were fixed in 10% neutral buffered formalin, embedded in OCT cryosectioning 
media (Tissue-Tek), and then snap frozen in a chilling bath.  50 µm tissue sections were 
taken using a Microm Cryo-Star HM 560MV cryostat (Thermo Fischer) and attached to 
Superfrost Plus slides.  Glass coverslips were mounted using ProLong Gold antifade 
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mounting media with DAPI (Invitrogen Corp.) to visualize c ll nuclei.  In the live versus 
devitalized cell QD study, one rat each from the live hMSC group, devitalized hMSC 
group, and HEK group (each originally treated with six million cells per scaffold) was 
sacrificed 4 weeks after surgery.  Animals were chosen that displayed average defect 
fluorescence intensity per group as assessed by IVIS scan quantification.  Femurs were 
collected, embedded in OCT media, snap frozen, and then sectioned in 20 µm slices.  All 
sections were fixed in 4% formaldehyde in PBS and then permeabilized with acetone.  
Sections prepared for human nuclei staining were blocked with 5% donkey serum 
followed by application of a mouse anti-human nuclear antige  monoclonal primary 
antibody (HuNu, Millipore MAB1281).  Sections prepared for rat macrophage staining 
were blocked with 5% bovine serum albumin followed by application of a mouse anti-rat 
CD68 primary antibody (AbD Serotec, MCA341R). Next a fluorescent Alexa Fluor® 
488 donkey anti-mouse (Invitrogen) secondary antibody was applied to all sections 
followed by 5 ng / mL DAPI counter-staining.  Control sections for each immunolabel 
excluded primary antibody staining. 
In Vitro Human Stem Cell Nuclear Labeling:  For 2D in vitro human cell 
nuclear labeling, 100,000 hMSCs were seeded on single-well Lab-Tek chambered cover 
glass slides and allowed to adhere overnight.  Cells were fixed in 10% neutral buffered 
formalin, permeabilized with acetone, and then blocked in 5% donkey serum followed by 
application of HuNu monoclonal antibody.  Next a fluorescent Alexa Fluor® 488 donkey 
anti-mouse secondary antibody was applied followed by 5 ng / mL DAPI counter-
staining.   
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Data Analysis:  Data were analyzed using GraphPad Prism 5 software.  Analyses 
comparing three or more groups were analyzed using ANOVA with Tukey post hoc 
analyses for pairwise comparisons.  Analyses comparing two groups were analyzed using 
unpaired t-tests.  Whenever required, the raw data was tran fo med using a natural 
logarithmic transformation to make the data normal and the variance independent of the 
mean (Kutner 2005) prior to statistical analysis.  If after transformation data still was not 
normal or variance independent of the mean, data sets were analyzed using the Kruskal-
Wallis non-parametric test followed by Dunn’s multiple comparison test.  For the 
comparisons of defect site QD fluorescence, repeated measures ANOVA was performed 
with Bonferroni post tests. For the in vivo live versus devitalized stem cell study, no 
significant differences in defect fluorescence were observed between defects treated with 
three or six million hMSCs, between defects treated with live or dead stem cells, or 
between their contralateral acellular control defect sites, so groups were pooled into 
defects that originally were treated with scaffolds seeded with QD-loaded cells and those 
treated with acellular scaffolds.    HEK cell data are shown but not included in statistical 
analyses due to small sample size.  Data are presented as mean ± standard error of mean 
(SEM).  A p-value < 0.05 was considered significant. 
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Chapter 4: Results 
In Vitro Stem Cell Labeling with Quantum Dots: Fluorescence microscopy 
images revealed a clear fluorescent signal in all wells containing QD-loaded MSCs 
(Figure 4.1).  While there qualitatively appeared to be minimal differences in 
fluorescence between QD types and even between different QD concentrations, 18-hour 
QD incubation increased QD internalization compared to one-hour incubation. QDs were 





When plates were imaged using an IVIS Lumina system, increased fluorescence 
was confirmed in cells exposed to QDs for 18 hours compared to one hour (Figure 4.2).   
There was also a qualitative difference in fluorescence between QD types, with the cells 
FIGURE 4.1: Fluorescence microscopy images showing quantum dot-labeled 
rMSCs in 2D culture after incubation with quantum dots for 1 hour or 18 hours. 
Note presence of red quantum dots in cytoplasmic space surrounding blue nuclei 
counterstained with DAPI (D).  40X magnification.  QT - QTracker 800 QDs, ITK - 
QDot ITK 800 QDs 
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loaded with QTracker QDs (QT) emitting a stronger signal th n those loaded with QDot 




Both fluorescence microscopy and IVIS imaging showed a cle r fluorescent 
signal in QD-loaded rat MSCs, hMSCs, and hAFS Cells, indicating QD uptake in 
multiple stem cell sources and species (Figure 4.3). 
FIGURE 4.2: Comparison of fluorescence emission from quantum dot-loaded rMSCs 
after either 1 or 18 hour incubation as assessed by IVIS Lumina fluorescent imaging.  





Quantum Dot Effects on 2D In Vitro Cell Viability : Live / Dead staining 
revealed that all QD-loaded stem cells remained viable exc pt for one particular group, 
the QTracker-loaded rMSCs at the highest QD concentration of 20 nM (Figure 4.4).  This 
finding agrees with the literature that QDs can have cytotoxic effects in vitro, but 
FIGURE 4.3: Comparison of fluorescence emission from rMSCs, hMSCs, and 
hAFS Cells as assessed by either A) IVIS imaging or B) fluorescence microscopy.  
Microscopy images shown for 10 nM QD concentration.   20Xmagnification. 
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generally only at higher concentrations.  Based on our in vitro results, we opted for 
incubating cells in 5 nM concentration QTracker 800 QDs for 18 hours for our in vivo 




In Vivo Segmental Defect Delivery of QD-Labeled Stem Cells – Preliminary 
Cell Source Comparison: Immediately after implantation, IVIS scans revealed a clear 
fluorescent signal at right hindlimb defect sites that received scaffolds seeded with QD-
labeled stem cells from both cell sources (Figure 4.5).  Unexpectedly, after one week a 
signal was detected at not only the right hindlimb defect sites, but also at the left 
hindlimb control sites which originally received only acellular scaffolds, suggesting 
possible migration of implanted stem cells.  Clear defect site fluorescent signals persisted 
throughout the duration of the 12-week study. 
FIGURE 4.4: Fluorescence microscopy images showing presence of live (green) 
cells and dead (red) cells after Live / Dead stain with calcein / ethidium.  Quantum 
dots only had negative effects on cell viability at the highest concentration of 20 nM 




Fluorescent signal intensity at defect sties treated with scaffolds seeded with QD-
labeled stem cells decreased rapidly within the first 2 weeks of the study and then 
decreased slowly during the rest of the study, but remained above ackground levels 
(Figure 4.6A).  In contrast, fluorescent signal intensity at contralateral defect sites treated 
with acellular scaffolds increased after one week and then decreased throughout the rest 
of the study.   Significant differences in fluorescence int nsity were observed between 
defects treated with cells and control defects through the first week of the study (Figure 
4.6B).   Observed fluorescence patterns and intensities were similar for all animals, 
regardless of stem cell source.  There were no observed signs of negative effects from 
QD exposure on animal morbidity or mortality throughout the study.  
FIGURE 4.5:  In vivo quantum dot fluorescence – preliminary study. Initial 
fluorescent signals were observed only at right hindlimb defect sites treated with 
scaffolds seeded with QD-loaded stem cells, but after on week and for the remainder 
of the study the signal was present in both right and left hindlimbs in all rats. Results 
from delivery of a scaffold seeded with QD-labeled hMSCs are shown; similar signals 




The presence of fluorescent QDs at defect sites was confirmed in histological 
cryosections, which revealed QDs amidst DAPI-stained cell nuclei within the PCL 
scaffold (Figure 4.7A).  QD concentration was qualitatively higher in the right hindlimb 
defect sites originally implanted with QD-loaded cells, and QDs in the defects originally 
treated with acellular scaffolds were primarily located near the scaffold interface with the 
bordering fibrous tissue.  QDs were also detected in the kidneys as well as the organs of 
FIGURE 4.6: Defect site fluorescence intensity quantification.  A) Comparison of 
fluorescence emission levels in defect sites originally treated with scaffolds seeded 
with QD-loaded stem cells and sites originally treated with acellular control scaffolds; 
note peak in control hindlimb fluorescence after one week.  Fluorescence count values 
remained above background levels observed in an unoperated control rat.  B) 
Comparison of fluorescence emission between grouped cellular and acellular defects.  
* p < 0.05 
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the reticuloendothelial system (RES) including the liver, spleen, and lymph nodes, 





In Vivo Segmental Defect Delivery of QD-labeled Stem Cells – Analysis of 
Quantum Dot Fate After Induced Cell Death: Immediately after surgery a fluorescent 
signal was detected at defect sites treated with either liv  or devitalized constructs 
containing QD-labeled cells but not at the contralateral sites treated with acellular 
scaffolds.  After ten days, all defect sites displayed a cle r fluorescent signal, including 
those treated with acellular scaffolds contralateral to defects treated with QD-containing 
devitalized hMSCs or human embryonic kidney 293 (HEK) cells (Figure 4.8).   
FIGURE 4.7: Quantum dot fluorescence in histological cryosections - preliminary 
study.  A) Quantum dots (red) and DAPI-stained cells (blue) within pore spaces of 
PCL scaffolds delivered to bone defect sites.  4X magnificat on. (B) Quantum dots 




There were no significant differences in defect site fluorescence between live or 
devitalized cell constructs or between constructs seeded with three or six million cells 
(Figure 4.9).  As a group, defects treated with constructs containing QD-loaded cells 
displayed a significantly higher fluorescent signal than defects treated with acellular 
scaffolds only at the day of surgery.  By the tenth day after surgery defect fluorescence 
intensity was similar in all defect sites. 
 
 
FIGURE 4.8:  In vivo quantum dot fluorescence – live versus devitalized hMSCs 
study. Femoral defect site fluorescence 10 days after bone defects were treated by 
delivery of scaffolds containing either 3 or 6 million QD-loaded live hMSCs, 3 or 6 
million QD-loaded devitalized (dead) hMSCs, or 6 million QD-loaded HEK cells, 





Immunostaining was performed to identify the cell types which were associated 
with the QDs in rats sacrificed four weeks post-surgery.  An antibody specific for human 
nuclei (HuNu) was first shown to effectively label hMSCs in 2D in vitro conditions 
(Figure 4.10A).  Analysis of histological tissue sections taken from defects treated with 
live hMSCs, devitalized hMSCs, or HEK cells, as well as their contralateral defects, 
revealed positive HuNu / QD staining in only the live hMSCs and HEK cells 
implantation sites (Figure 4.10B). However, staining with a rat CD68 macrophage 
antibody revealed extensive positively stained cells in all groups (Figure 4.10C).  At the 
cell delivery defect site, QDs were found both colocalized with and independent from the 
stained macrophages in the live hMSC and live HEK construct but not the devitalized 
hMSC constructs.  Interestingly, the acellular site contralateral to live hMSC constructs 
also contained QDs colocalized with and independent from the stained macrophages.  In 
FIGURE 4.9:  Quantification of in vivo quantum dot fluorescence – live versus 
devitalized hMSCs study.  A) Comparison of fluorescence levels in all individual 
groups.  B) Comparison of fluorescence levels in defects treated with scaffolds seeded 




contrast, the acellular sites contralateral to dead hMSC or live HEK constructs only 




Unlike in the previous study treating segmental defects with QD-free hMSCs, no defects 
were bridged by 12 weeks post-surgery (Figure 4.11).   
 
FIGURE 4.10:  Immunolabeling to identify cell types associated with quantum dots.  
A) 2D in vitro labeling of hMSCs with DAPI and HuNu human nuclear antibody.  
20X magnification. B) Cells labeled with HuNu from defects treated with 6 million 
live hMSCs or 6 million HEK cells.  Green-hMSCs, Blue-DAPI, Red-QDs.  40X 
magnification. C) Cells labeled with CD68 rat macrophage antibody. Green-
macrophages, Blue-DAPI, Red-QDs.  Arrowheads point to QDs colocalized with 





There were no significant differences in i  vivo or post mortem defect bone 
volumes (Figure 4.12A) or maximum torque and torsional stiffness (Figure 4.12B) 
between groups.  The values observed from the QD-free hMSC treated defects used in 
the first experiment are shown as dashed black lines.  There were no observed signs of 
negative effects from QD exposure on animal morbidity or mortality throughout the 
study. 
FIGURE 4.11:  Qualitative defect site mineral formation after in vivo delivery of live 
or devitalized QD-loaded hMSCs. A) Radiographic (upper) and in vivo Micro-CT 
(lower) images of the representative bone formation per group in defects receiving 
QD-labeled live hMSC scaffold, acellular scaffold contralateral to live hMSC 
scaffold, QD-labeled devitalized hMSC scaffold, or acellular scaffold contralateral to 
devitalized hMSC scaffold.  
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In Vitro Quantum Dot Effects on Stem Cell Osteogenic Differentiation:  
Finally, although there was a reduced healing response in segmental d fects treated with 
QD-loaded hMSCs compared to defects treated with QD-free hMSCs, quantum dot 
loading did not reduce in vitro hMSC osteogenic differentiation as assessed by 
qualitatively comparable mineral formation to QD-free hMSCs after Von Kossa assay 
(Figure 4.13A,B). 
FIGURE 4.12:  Quantitative comparison of structure and functio  results from in vivo 
delivery of scaffolds seeded with live or devitalized QD-loaded hMSCs as well as 
acellular contralateral control scaffolds. A) In vivo and post mortem mineral formation 
within defect sites. B) Biomechanical properties of femurs tested to failure in torsion.  
Dashed lines represent average values from defects treated with scaffolds seeded with 
QD-free hMSCs as displayed in Chapter 3 (data from the we k 12 time point are 




FIGURE 4.13: In vitro quantum dot effects on hMSC osteogenic differentiation.  A) 
View of gross mineral formation in wells containing hMSCs with or without QDs.  
B) View of magnified mineral nodules.  20X magnification. 
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Chapter 4: Discussion 
 
Stem cell-mediated functional regeneration of segmental bone defects may be 
limited by short-term cell viability or cell migration from the defect site.  This possibility 
led us to investigate the fate of delivered cells by labeling them with fluorescent quantum 
dots.  In a preliminary study, we observed strong quantum dot fluorescence in vivo at the 
defect site for at least twelve weeks after implantation of scaffolds seeded with QD-
loaded stem cells.  Interestingly, contralateral defect sites treated with acellular scaffolds 
began to display clear fluorescent signals one week after implantation, suggesting the 
possibility that delivered QD-containing stem cells may have homed to the area of tissue 
damage, which has been reported by multiple groups as an ability of hMSCs 
(Chamberlain, Fox et al. 2007), (Kumagai, Vasanji et al. 2008), (Karp and Leng Teo 
2009), (Laird, von Andrian et al. 2008).  The rapid reduction in fluorescent signal 
strength during the first two weeks of the study could be explained by cell migration from 
the defect site or by cell death followed by QD clearance and sequestration in the organs 
of the RES.  Later decreases in signal strength could be due to QD redistribution amongst 
dividing cells, leading to a smaller concentration of QDs per cell. The presence of QDs at 
defect sites and in RES organs was confirmed by histology.  Observing QDs in RES 
organs substantiated reports that free QDs would not enter neighboring cells but rather 
enter the circulation and become sequestered in RES organs (Rosen, Kelly et al. 2007), 
(Voura, Jaiswal et al. 2004), (Ballou, Lagerholm et al. 2004).     
In order to confirm that QDs were in fact associated with the delivered stem cells 
in both original implantation and initially acellular contralateral sites, a second study was 
performed in which scaffolds were implanted that contained either live or devitalized 
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QD-loaded hMSCs or QD-loaded non-stem HEK cells.  The observation of contralateral 
fluorescence in all defect sites after 10 days suggested that, at least in the devitalized 
group, QDs were no longer associated with hMSCs because dead cells would have no 
ability to migrate.  Immunostaining revealed that while a small population of QDs was 
still associated with hMSCs in the live cell and HEK cell groups, no human cells were 
detected in contralateral limbs and the majority of QDs in all groups were associated with 
host macrophage cells.  This finding agrees with a recent report that QTracker 565 QDs 
injected into mice accumulated in murine CD68+ macrophages in atherosclerotic legions 
(Buono, Anzinger et al. 2009).  The mechanism through which QDsdelivered at one 
local injury became associated with macrophages in a separat  local injury site remains 
unclear.  Additionally, while 5 nM concentration QD-labeling caused no observed 
negative effects on cell viability or osteogenic differentiation capacity in vitro, QD-
loaded live hMSCs failed to enhance bone formation or bridge any defects.  This is in 
contrast to the previous study without QDs in which there was a significant effect of stem 
cell implantation on bone ingrowth and biomechanical properties and bridging was 
observed in 4/9 animals receiving hMSCs.  The reduction in bridging could be caused by 
either a reduction in stem cell osteogenic differentiation capacity or in stem cell viability, 
possibly due to cadmium toxicity and an elevated macrophage infiltration response.  The 
combination of false positive fluorescence signals from QDs taken up by host cells as 
well as the apparent reduction in in vivo healing capacity of constructs loaded with QD-
loaded stem cells compared to constructs loaded with QD-free stem cells suggests that an 
alternate in vivo tracking agent is needed to evaluate the distribution and viability of 
delivered stem cells during the segmental defect healing process.   
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Chapter 5 
ADENO-ASSOCIATED VIRUS (AAV) TRANSDUCTION OF HUMAN STEM 
CELLS WITH OSTEOGENIC CUES TO ENHANCE BONE FORMATION  
Chapter 5: Introduction 
 While bone tissue engineering therapies delivering stem c lls alone can serve as 
effective treatments, inclusion of added cues that push stem cells towards osteogenic 
differentiation and stimulate them to produce bone matrix can greatly improve treatment 
efficacy.  Many bone defect therapies have investigated delivery of osteoinductive 
proteins, and chief amongst them are the bone morphogenetic proteins (BMPs).  
 Recombinant human BMP2 (rhBMP2) has been used to increase healing of 
critically-sized defects in rabbit, sheep, dog, and especially rat models (Yasko, Lane et al. 
1992), (Lee, Shea et al. 1994), (Oest, Dupont et al. 2007), (Ohura, Hamanishi et al. 
1999).  The rhBMP2 is usually delivered on carriers such as demineralized bone matrix 
or collagen sponges.  There have also been clinical trials involving rhBMPs, including 
application of rhBMP7 to large fibular defects (Geesink, Hoefnagels et al. 1999) and 
tibial nonunions (Friedlaender, Perry et al. 2001), (Govender, Csimma et al. 2002) as well 
as rhBMP2 application to aid in spinal fusion.  Success in these clinical trials led the US 
Food and Drug Administration to approve application of rhBMP2 on absorbable collagen 
sponges for single-level interbody fusions of the lumbar spine (InFuse  - Medtronic) 
(Einhorn 2003) and grant a Humanitarian Device Exemption for delivery of rhBMP7 
(also called OP-1) on collagen carriers (The OP-1 Device – Stryker) to treat nonunions 
that have failed to respond to other treatment modalities (Lieberman, Daluiski et al. 
2002).  However, the extremely high supraphysiological doses f rhBMP2 that have been 
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required to heal these bone defects can cause problems such as inflammation or ectopic 
bone formation due to the initial rapid burst release of pr teins from the carriers (Cahill, 
Chi et al. 2009).  The high costs of these therapies also prohibit them from being widely 
used.  While BMP-based therapies have largely been shown to be effective for healing 
bone defects, a better method for BMP production and delivery is needed.    
One possible alternative to delivery of large doses of rhBMPs to treat bone 
defects is to program cells to increase their production of these proteins by gene therapy 
techniques.  Due to its superior safety compared to other viral vectors, AAV likely has 
the highest potential of all viral vectors for use in treating large bone defects in humans.  
AAV preclinical in vivo studies have been performed in a variety of animal species 
(predominantly mouse, rat, dog, and primate) providing treatm nt for a variety of 
conditions (including hemophilia, cystic fibrosis, Duchenne muscular dystrophy, and 
rheumatoid arthritis) (Coura Rdos and Nardi 2007).  At least two clinical trials have been 
performed using rAAV, one an in vivo approach treating cystic fibrosis and one an ex 
vivo approach treating haemophilia B, but no trials have occurred yet to treat bone and 
joint diseases, likely due to their less fatal nature (Ulrich-Vinther 2007). In the cystic 
fibrosis trial more than 100 patients were treated with AAV-CFTR therapy applied by 
aerosol spray (Moss, Milla et al. 2007).  While this study di  not lead to any significant 
improvements in patients, no adverse health effects were reported in response to AAV, 
and the lack of efficacy could possibly be due to an ineffici nt aerosolized in vivo 
delivery.   In two preclinical studies, direct injection of either AAV-BMP2 or AAV-
BMP4 vectors into immunocompetent rat hindlimb muscle led to significant ectopic 
mineral formation (Chen, Luk et al. 2003), (Luk, Chen et al. 2003), but injection offers 
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limited control of viral particle distribution, which could limit transduction efficiency or 
lead to undesirable ectopic bone formation away from bone defect sites.  These results 
call for a better in vivo AAV delivery method.   
Schwarz and colleagues have recently developed a novel in ivo AAV delivery 
method in a murine allograft model (Ito, Koefoed et al. 2005), (Koefoed, Ito et al. 2005), 
(Awad, Zhang et al. 2007).  Their main research goal was to try to overcome the poor 
performance of allografts, as described above, through AAV gene therapy.  They first 
used a DNA microarray to find that the main difference in gene expression between 
allografts and autografts was a lack in expression of vascular endothelial growth factor 
(VEGF), a stimulator of angiogenesis, and receptor activ tor of nuclear factor κ-B ligand 
(RANKL), which is important in fracture callus formation and osteoclastic resorption of 
bone during remodeling.  Next they lyophilized AAV-RANKL and AAV-VEGF particles 
in a 1% sorbitol solution onto the murine allografts.  When these AAV-coated allografts 
were implanted in vivo into large bone defects stabilized with intramedullary pins, the 
allografts underwent neovascularization and remodeling within 4 weeks, similar to 
autografts (Ito, Koefoed et al. 2005).  They used rAAV-LacZ coated allograft controls to 
determine the in vivo transduction efficiency.  LacZ is a reporter gene thatencodes for β-
Galactosidase (β-Gal), and locating cells producing this protein can be achieved through 
histological staining with X-Gal (Holt and Sadler 1958).  Although their transduction 
efficiency was low (1-5% of the cells directly surrounding the allografts), it was clearly 
high enough to cause a significant improvement in allograft integration and revitalization.  
Furthermore, they found that since AAV is thermostable, AAV-coated allografts could be 
frozen for months with only minor negative effects on transduction ability.   
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Next they coated allografts with AAV containing the DNA to encode for the 
constitutively active form of activin receptor-like kinase 5 (CaAlk2), an active BMP 
receptor, and implanted them into murine segmental defects.  They found that AAV-
CaAlk2 coated allografts lacked foreign body reactions, had a bone collar formed along 
the surface of the allografts, had live bone marrow within allografts, and experienced 
osteoclastic resorption of allografts (Koefoed, Ito et al. 2005). However, they also found 
that the nonporous cortical surface of allograft bone prohibits uniform distribution of the 
rAAV / 1% sorbitol / PBS solution coating prior to freeze-drying.   
They then found that demineralization of the allograft surfaces, which created 
voids within the cortical bone, increased surface adsorption of rAAV-Luciferase coatings 
and led to longer gene expression of luciferase compared to undemineralized allografts as 
assessed by continued display of in vivo bioluminescence (Yazici, Yanoso et al. 2008). 
Peak gene expression was delayed to one week post-surgery, which coincides with the 
end of the inflammatory phase of long bone injury response and the initiation of the 
reparative phase of bone healing.  If an osteogenic gene w r  delivered in this manner 
and had similar expression kinetics, it might provide a significant improvement in bone 
development compared to delivery of recombinant proteins, which have very fast release 
kinetics that would likely occur during the initial inflammatory response phase of bone 
healing when there are many complicating and confounding signal  present.  In one 
recent study, lyophilization of AAV-BMP2 onto hydroxyapatite scaffolds led to 
significant ectopic bone formation four weeks after implantation into muscle pouches in 
the backs of rats (Nasu, Ito et al. 2009).  The results of these studies lead us to 
hypothesize that using a similar AAV-BMP2 gene lyophilization procedure to coat 
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porous polymer scaffolds prior to stem cell seeding could produce an effective therapy 
for healing critically-sized large bone defects in our rat model. 
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Chapter 5: Materials and Methods 
 
Scaffold Preparation / AAV Coating - PLDL Scaffolds: 85% porous polymer 
poly(L-Lactide co-D,L-Lactide 70:30) (PLDL) cylindrical scaffolds, 8 mm length and 4 
mm diameter, were fabricated as previously described (Lin, Barrows et al. 2003), (Oest, 
Dupont et al. 2007).  Briefly, scaffolds were created by coating 100-micron removable 
stainless steel fibers with a 70% / 30% mixture of liquid PLDL and the porogen 
azodicarbonamide to create longitudinally oriented macroporosity, while decomposition 
of the porogen with the addition of heat produced random microporosity. Scaffolds were 
then sterilized by gamma-irradiation (2.5 Mrad). Finally scaffolds were coated with 
5*1010 rAAV-LacZ particles (Gene Core Facility, University of North Carolina, Chapell 
Hill, NC) in 100 µL of 1% sorbitol / PBS solution through lyophilization by collaborators 
at the University of Rochester.   All rAAVs used in theexperiments described in this Aim 
were serotype 2 and were under the transcriptional control of the cytomegalovirus (CMV) 
promoter. 
Scaffold Preparation / AAV Coating - PCL Scaffolds: 85% porous PCL 
cylindrical scaffolds, 8 mm length and 5 mm diameter, were fabricated as described in 
Chapter 3.  All scaffolds were coated with GFOGER and lyophilized type I collagen. 
Scaffolds were then placed in the wells of custom molds and coated with either 1010 
scAAV2.5-BMP2 or AAV-Luciferase (AAV-Luc, Gene Core Facility, University of 
North Carolina, Chapell Hill, NC) particles in 100 µL of 1% sorbitol / PBS solution by 
lyophilization by collaborators at the University of Rochester.  The adeno-associated 
virus used in this study to deliver the BMP2 transgene was a modified form of the 
traditional AAV virion that was developed at the University of Rochester.  Traditional 
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AAV has inefficient transgene expression due to the need for uplication of the single-
stranded DNA genome prior to transgene expression; however the modified scAAV 
features self-complimentary DNA strands, increasing the efficiency of transgene 
expression in MSCs (Kim, Lee et al. 2007).   
Cell Culture / AAV Transduction – 2D In Vitro scAAV2.5-BMP2 / AAV-Luc: 
20,000 hMSCs (p4) or hAFS Cells (p19) were seeded in wells of 24-well plates and 
allowed to adhere for 24 hours.  One mL standard culture media described previously 
was then added to one group of cells, culture media supplement d with the osteogenic 
supplements 10 mM β-glycerol phosphate and 50 µg / ml ascorbic acid 2-phosphate was 
added to the second group, culture media / osteogenic supplements and AAV-Luc viral 
particles were added to the third group, and culture media / osteogenic supplements and 
scAAV2.5-BMP2 viral particles were added to the fourth group (n = 5 per group).  For 
viral transduction, 0.5*109 scAAV2.5-BMP2 or control AAV-Luc particles were added 
per well in 10 µL media and gently agitated for AAV distribution, producing an initial 
estimated multiplicity of infection (MOI – ratio of number of viral particles to number of 
cells) of 2.5*104. After 10 minutes 1 mL of media was added per well and plates were 
cultured at 37°C / 5% CO2 in an incubator.  Media supernates were collected and media 
changed at day 2, 6, 9, 13, and 16.  Supernate BMP2 levels were assessed using an 
ELISA assay (BMP2-Immunoassay Kit, Quantikine, Cat. #DBP200, R&D Systems).  
Cell lysates were collected at day 16 and used to determine DNA content through a 
PicoGreen DNA Assay.  The same lysates were used in an alk line phosphatase activity 
assay to assess osteogenic differentiation.  In this assay, the release of p-nitrophenol from 
p-nitrophenyl phosphate by the ALP enzyme is measured (Martin, Dean et al. 1996). The 
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ALP substrate working solution was made by mixing equal parts of 20 mM p-nitrophenyl 
phosphate, 1.5 M 2-Amino-2-Methyl-1-Propanol (pH 10.25) and 10 mM MgCl2. The 
experimental samples were mixed with the freshly made substrate working solution, and 
incubated for 1 hour at 37° C. The reaction was stopped by adding 1N NaOH, and the 
absorbance was measured at 405 nm on a plate reader (PowerWave XS, Biotek, VT). All 
samples were run in triplicate and compared to p-nitrophenol standards. 
Cell Culture / AAV Transduction – 2D In Vitro AAV-LacZ:  hMSC’s (p4) 
were cultured on 6-well plates at a density of 2,000 cells/m2 (total cells = 19,200 / well) 
in culture media.  After 24 hours either 5*108 (1X dose) or 109 (2X dose) rAAV-LacZ 
viral particles in 100 µL of PBS were added to the cells in either 3 mL culture media 
(High transduction volume) or in 500 µL culture media followed by addition of 2.5 mL 
media after 3 hours (Low transduction volume) (n = 3 per dose per transduction volume).  
After 3 or 6 days cells were fixed in 0.2% glutaraldehyde and stained with X-Gal for 10 
hours followed by counterstaining with nuclear fast red for 60 seconds.  X-Gal positive 
cells were counted and then total cell numbers were calculated by 5 ng / mL DAPI 
staining followed by cell nuclei counting using fluorescence microscopy images and the 
image analysis software ImageJ.  hMSCs were also cultured in wells of an additional 6-
well plate, and after 24 hours cells were fixed in 0.2% glutaraldehyde and stained with 5 
ng / mL DAPI, followed by cell nuclei counting in order to quantify average initial 
number of cells present at the time of transduction (n = 3) for accurate MOI assessment.   
Cell Culture / AAV Transduction – 3D In Vitro scAAV2.5-BMP2 / AAV-Luc:  
One million hMSCs or hAFS Cells in 100 µL culture media were seeded on PCL 
scaffolds previously coated with 1010 lyophilized AAV particles for an initial MOI of 104.  
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After seventy-five minutes incubation, 5 mL of culture media supplemented with 
osteogenic supplements (10 mM β-glycerol phosphate and 50 µg / ml ascorbic acid 2-
phosphate) was added to each well of the 12-well plates in which the scaffolds were held, 
and scaffolds were cultured dynamically on rocker plates for 12 weeks.  Media 
supernates were collected and media changed every three days for eleven weeks. n = 5 
per cell type per AAV gene.  Supernate BMP2 levels were ass ss using an ELISA assay 
(BMP2-Immunoassay Kit, Quantikine, Cat. # DBP200, R&D Systems).   
Cell Culture / AAV Transduction – 3D Scaffold Stem Cell Pre-Seeding For 
In Vivo scAAV2.5-BMP2 / AAV-Luc Study: Three million hMSCs were seeded on 
PCL scaffolds previously coated with 1010 lyophilized scAAV2.5-BMP2 or AAV-Luc 
particles for an initial MOI of 0.333*104.  Cells were seeded on scaffolds in 100 µL 
culture media and after 75 minutes 4 mL of culture media was added to each well of the 
12-well plates in which the scaffolds were held.  Scaffolds were then cultured for two 
days prior to in vivo implantation.   
Assessment Of In Vitro Cell Viability / DNA Analysis: Cell viability of stem 
cells seeded on 3D scaffolds was assessed at the end of the twelve week study by Live / 
Dead staining of one scaffold per AAV coating per cell source followed by fluorescence 
microscopy imaging as described in Chapter 3.  Scaffolds cho en for viability assessment 
displayed the average mineral volume per group at the 12-week scan time point.  The 
remaining four scaffolds per group were used to quantify DNA levels following the same 
methods described in Chapter 3.  Cell lysates from 24-well plates in the 2D AAV-Luc / 
AAV-BMP2 study were collected and DNA was extracted into PBS solution by freeze-
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thaw cycles and repeated vortexing of sample tubes.  DNA levels were measured by 
PicoGreen assay (n = 5 / group) 
Surgical Technique – Segmental Defect Treatment With scAAV2.5-BMP2 Or 
AAV-Luc Coated PCL Scaffolds, With Or Without Pre-Seeded hMSCs: All surgical 
techniques were approved the Georgia Institute of Technology Institute Animal Care and 
Use Committee (protocol A08066).  Critically-sized femoral defects were created in 13-
week old female Nude rats as described previously in Chapter 3.  Defects were treated 
with one of four constructs:  PCL scaffold coated with scAAV2.5-BMP2 or AAV-Luc (in 
vivo gene therapy – a variety of local host cells could be transduced), or PCL scaffold 
coated with scAAV2.5-BMP2 or AAV-Luc pre-seeded with three million hMSCs (in 
vitro gene therapy – specifically selected cells are transduced, here hMSCs).  Sample size 
was n = 10 per group.   
Surgical Technique – Segmental Defect Treatment With AAV-LacZ-Coated 
PLDL Scaffolds To Assess Short-Term In Vivo Transduction:  Critically-sized 
femoral defects were created in 13-week old female Sasco Sprague Dawley rats as 
described previously in Chapter 3.  Defects were treated with either PLDL scaffold or 
PLDL scaffold previously coated with AAV-LacZ viral particles (n = 3 / group).  
Animals were sacrificed after two weeks.     
Preparation of Histological Cryosections From In Vivo rAAV-LacZ Study:   
Femurs were harvested, fixed in 0.2% glutaraldehyde, washed with PBS, embedded in 
OCT medium, and frozen at -80º C.  Femur / scaffold tissue cryosections five microns 
thick were obtained using a cryostat, as described above, and mounted on SuperFrost 
Plus glass slides.  Tissue sections were fixed again in 0.2%glutaraldehyde and then 
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stained with X-Gal and nuclear fast red and coverslipped.  Brightfield microscopy was 
used to obtain images showing both the PLDL scaffold and the soft tissue surrounding it. 
Radiograph / Micro-CT Imaging And Biomechanical Testing: 2D radiographs 
of segmental defect sites were obtained 4, 8, and 12 weeks post-surgery in the in vivo 
study comparing scAAV2.5-BMP2 and AAV-Luc treatments following procedures 
described in Chapter 3.  In vitro mineral formation on 3D scaffolds was measured by 
Micro-CT scans 3, 6, 9, and 12 weeks after stem cell seeding following procedures 
described in Chapter 3.  Mineral formation in segmental defects was measured by Micro-
CT scans performed in vivo at 4, 8, and 12 weeks post-surgery as well as in post mortem 
scans following procedures described in Chapter 3.  Post morte scans were performed 
using a density threshold corresponding to 385 mg HA/cm3.  Biomechanical torsional 
tests were performed on explanted femurs taken from rats sacrificed 12 weeks post-
surgery as described in Chapter 3.  Sample sizes for Micro-CT scans and torsional testing 
were n = 10 for scAAV2.5-BMP2 scaffold and scAAV2.5-BMP2 scaffold + pre-seeded 
hMSCs groups, n = 8 for the AAV-Luc scaffold + pre-seeded hMSCs group, and n = 6 
for the AAV-Luc scaffold group due to loss of two samples in which the polysulfone 
plate became detached from the stainless steel plates between weeks 8 and 12.   
 Data Analysis: Data were analyzed using GraphPad Prism 5 software.  Analyses 
comparing three or more groups were analyzed using ANOVA with Tukey post hoc 
analyses for pairwise comparisons.  Analyses comparing two groups were analyzed using 
unpaired t-tests.  Whenever required, the raw data was tran fo med using a natural 
logarithmic transformation to make the data normal and the variance independent of the 
mean (Kutner 2005) prior to statistical analysis.  If after transformation data comparing 
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three or more groups still was not normal or variance independent of the mean, data sets 
were analyzed using the Kruskal-Wallis non-parametric test followed by Dunn’s multiple 
comparison test.  For the comparisons of in vitro BMP2 release over time, repeated 
measures ANOVA was performed with Bonferroni post tests. For the in vivo segmental 
defect study comparing treatment with scAAV2.5-BMP2 scaffold with or without 
hMSCs and AAV-Luc scaffold with or without hMSCs, no significant differences were 
found between the two BMP2 groups or two Luc groups so they were each combined to 
increase sample size.  For the same study, no significa t differences were found in week 
4 or 12 in vivo mineral formation, max torque, or stiffness between th two hMSC-seeded 
scaffold groups and the two acellular scaffold groups so they were combined to increase 
sample size.  If after natural logarithmic transformation the grouped data variance was 
still not independent of the mean, Welch’s correction f r unequal variances was used in 
the unpaired t-test.  Also for the same in vivo segmental defect study, no significant 
differences in biomechanical properties were found between scAAV2.5-BMP2 scaffold-
treated defects that were either bridged or unbridged (as assessed by 2D radiograph 
evaluation), so the single group was split into the two bridged and unbridged groups for 
comparison of functional restoration with nude rat whole bones.  Data are presented as 
mean ± standard error of mean (SEM).  A p-value < 0.05 was con idered significant. 
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Chapter 5: Results 
 
Segmental Defect Site Delivery Of rAAV-LacZ Coated Scaffolds To Assess 
Transduction Efficiency In Vivo:  Clear β-galactosidase expression was found in all of 




No β-galactosidase expression was found in control defects treated with uncoated 
PLDL.  Transduced cells were found within the scaffolds (though primarily at the 
periphery) indicating scaffold cellular infiltration (Figure 5.1A).  Transduced cells were 
also found in the soft tissue surrounding the scaffolds (Figure 5.1B).  Transduction 
efficiency, as assessed by qualitative evaluation of β-galactosidase expression in and 
around the scaffolds, was comparable with that found in the s udies by the Schwarz group 
(Ito, Koefoed et al. 2005). 
Evidence Of 2D In Vitro scAAV2.5-BMP2 hMSC Transduction And 
Resulting Increase In Osteogenic Differentiation: Media samples taken from wells 
containing hMSCs transduced with scAAV2.5-BMP2 displayed significantly higher 
FIGURE 5.1: Histological cryosections showing blue β-galactosidase expression 
from both A) transduced cells that have infiltrated the PLDL scaffold and B) 
transduced cells in the fibrous tissue immediately surrounding the implanted rAAV-
LacZ coated scaffolds. 10X magnification. 
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BMP2 concentrations than media samples from wells containi g hMSCs or hAFS Cells 
transduced with AAV-Luciferase throughout the duration of the 16-day study (Figure 
5.2A).  By day six, media from scAAV2.5-BMP2-transduced hMSCs displayed peak 
BMP2 concentration which was also significantly higher than scAAV2.5-BMP2-
transduced hAFS Cells, and this continued throughout the rest of the study.  scAAV2.5-
BMP2-transduction of hAFS Cells failed to cause an increase in BMP2 concentration in 




After 16 days, alkaline phosphatase expression in cell lysates was measured to 
assess osteogenic differentiation of stem cells.  An endpoint of 16 days was chosen based 
upon preliminary studies performed by collaborators at the University of Rochester 
showing a peak in transient alkaline phosphatase expression from scAAV2.5-BMP2 
transduced cells at that time point.  ALP activity in hMSCs transduced with scAAV2.5-
FIGURE 5.2: 2D in vitro evidence of scAAV2.5-BMP2 transduction of hMSCs 
resulting in an increase in osteogenic differentiation.  A) BMP2 concentrations in 
harvested media samples from wells containing stem cells in osteogenic media after 
Day 0 transduction with scAAV2.5-BMP2 or AAV-Luc. B) ALP activity measured in 
cell lysates collected 16 days after groups C and D were transduced by AAV-Luc or 
scAAV2.5-BMP2, respectively.  C) DNA levels measured from cell lysates.  D) ALP 
activity normalized by DNA level per well.  *, +  both indicate p < 0.05. 
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BMP2 was significantly higher than in hMSCs and hAFS Cells cultured in non-
osteogenic media (Figure 5.2B), but when ALP levels were no malized by DNA content, 
scAAV2.5-BMP2 transduced hMSC levels were significantly higher t an all other groups 
(5.2D).  scAAV2.5-BMP2 transduction of hAFS Cells failed to cause an increase in ALP 
activity in cell lysates during the 16-day experiment.  Cells cultured in osteogenic media 
in the absence of scAAV2.5-BMP2 failed to experience any significant increases in ALP 
activity, most likely due to the lack of dexamethasone, a potent stimulator of stem cell 
osteogenic differentiation, in the media.  hAFS Cell DNA levels were significantly higher 
than hMSC DNA levels in all media condition groups, suggesting increased cell 
proliferation of hAFS Cells compared to hMSCs (Figure 5.2C).  Of particular importance 
was a significantly reduced DNA content in scAAV2.5-BMP2 transduced hMSCs 
compared to all other groups, suggesting reduced stem cell proliferation due to increased 
osteogenic differentiation.   
Evidence Of 3D In Vitro scAAV2.5-BMP2 hMSC and hAFS Cell 
Transduction and Resulting Increase in hMSC Osteogenic Differentiation:  BMP2 
concentrations in media samples from wells containing hMSCs seeded on scAAV2.5-
BMP2 coated scaffolds displayed an expression pattern similar to that in the 2D 
experiment, with a peak one week after transduction (Figure 5.3).  Interestingly, BMP2 
concentrations from wells containing hAFS Cells seeded on scAAV2.5-BMP2 coated 
scaffolds significantly increased above levels in all other groups but not until 7 weeks 
after transduction, and the BMP2 peak was nearly twice as high (7788.74 versus 4811.82 
pg/mL) and lasted for three times as long (Day 44-65 versus Day 4-11) in hAFS Cells 





Mineral formation in hMSC-seeded / scAAV2.5-BMP2 coated scaffolds was 
significantly higher than in hMSC-seeded / AAV-Luc coated scaffolds and hAFS Cell-
seeded / scAAV2.5-BMP2 coated scaffolds beginning at week 6 and continuing through 
weeks 9 and 12 (Figure 5.4A,B).  The lack of significant differences at week 3 suggests a 
delay in osteogenic differentiation, or at least in resulting mineral formation, behind 
BMP2 expression which peaked at day 7.  While BMP2 expression in hAFS Cell-seeded 
/ scAAV2.5-BMP2 coated scaffolds did significantly increas  after seven weeks, no 
FIGURE 5.3: 3D in vitro evidence of scAAV2.5-BMP2 transduction of hMSCs and 
hAFS Cells.  The figure shows BMP2 concentrations in harvested media samples 
from wells containing stem cells seeded on PCL scaffolds previously coated by 
scAAV2.5-BMP2 lyophilization.  *, + , B  all indicate p < 0.05 
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resulting increase in mineral formation occurred by week 12 of the study.  Live stem cells 
were observed throughout scaffolds from each group at week 12 (Figure 5.4C).  Live 
cells were found along the outer circumferential periphery of the cylindrical scaffolds, 
along the surface of a longitudinally cut cross section (representing cells at the center of 
the scaffolds), and on both the top and bottom surfaces of the scaffolds. As in the 2D in 
vitro study, DNA content of scaffolds seeded with hMSCs transduced with scAAV2.5-
BMP2 was significantly lower than scaffolds seeded with hMSCs transduced with AAV-
Luc (Figure 5.5), again likely due to increased stem cell differentiation resulting in 








FIGURE 5.4: Evaluation of osteogenic differentiation of stem cells seeded on 3D PCL 
scaffolds previously coated with lyophilized AAV.  A) Quantitative comparison of 
mineral volumes within PCL scaffolds.  *, + both indicate p < 0.05.  B) Representative 
Micro-CT images of mineral formation within scaffolds.  C) Live / Dead microscopy 
images of scaffolds showing live green cells along circumferential periphery of 









Comparison Of In Vivo And In Vitro scAAV2.5BMP2 Gene Therapy 
Approaches For Healing Critically-Sized Nude Rat Femoral Defects: Twelve weeks 
post-surgery, bony bridging occurred in 5/10 defects treated with scAAV2.5-BMP2 
coated scaffolds alone, 3/10 defects treated with scAAV2.5-BMP2 coated scaffolds 
seeded with hMSCs pre-implantation, 1/6 defects treated with AAV-Luc coated scaffolds 
alone, and 0/8 defects treated with AAV-Luc coated scaffolds seeded with hMSCs pre-
implantation.  Note that mineral formation was restricted to the immediate vicinity of the 
segmental defect site, suggesting that BMP2 delivery via scAAV2.5-BMP2-coated 
polymer scaffolds avoided the ectopic bone formation that can be associated with bolus 
delivery of large doses of recombinant BMP2.  Representative defect mineral formation 
in each group is shown in Figure 5.6, both in radiograph images from weeks 4 and 12 and 
in corresponding week 12 Micro-CT images. 




 Quantitative comparison of Micro-CT-measured mineral volumes revealed 
significantly higher mineral formation in the scAAV2.5-BMP2 coated scaffold treatment 
group compared to the AAV-Luc coated scaffold treatment and the hMSC pre-seeded 
AAV-Luc scaffold treatment groups at week 8 in vivo as well as in post mortem scans 
(Figure 5.7A,B).  A significant difference in mineral volume existed between the 
scAAV2.5-BMP2 scaffold treatment group and the hMSC pre-seeded AAV-Luc scaffold 
group at week 12.  Biomechanical torsional testing revealed significantly higher 
FIGURE 5.6:  Qualitative defect site mineral formation after in vivo delivery of AAV-
coated PCL scaffolds with or without pre-seeding of hMSCs. A) Radiographic (upper) 
and in vivo Micro-CT (lower) images from defects which had the representative 
mineral formation per group. 
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maximum torque and torsional stiffness in the scAAV2.5-BMP2 scaffold treatment group 





 Comparison of grouped scAAV2.5-BMP2 therapies with grouped AAV-Luc 
therapies showed significant differences in both in vivo and post mortem mineral volumes 
(Figure 5.8A) as well as maximum torque and torsional stiffness (Figure 5.8B).  
FIGURE 5.7:  Quantitative comparison of structure and functio  results from in vivo 
delivery of AAV-coated scaffolds with or without pre-seeding of hMSCs. A) In vivo 
mineral formation within defect sites. B) Post mortem mineral formation within defect 
sites C) Biomechanical properties of femurs tested to failure in torsion.  Dashed lines 
represent average values from defects treated with non-AAV scaffolds seeded with 
hMSCs as reported in Chapter 3 (in vivo mineral formation from the week 12 time 





 Defects treated with scAAV2.5-BMP2 scaffolds were divided into bridged and 
unbridged groups and biomechanical properties were compared with age-matched whole 
nude rat femurs as a measure of functional restoration of native bone properties (Figure 
5.9).  Maximum torque values in bridged scAAV2.5-BMP2 treated defects were 41% of 
the values in whole nude femurs (0.126 N-m versus 0.307 N-m).  Torsional stiffness 
values in bridged scAAV2.5-BMP2 treated defects were 44% of the values in whole nude 
femurs (0.010 N-m/° versus 0.023 N-m/°) and were not significantly different from 
whole nude femurs.  
FIGURE 5.8:  Quantitative comparison of structure and functio  results from in vivo 
delivery of scAAV2.5-BMP2 treatments or AAV-Luc treatments. A) In vivo and post 
mortem mineral formation within defect sites.  B) Biomechanical properties of femurs 




 Comparison of grouped hMSC-seeded scaffold therapies with grouped acellular 
scaffold therapies showed significantly higher week 12 in vivo mineral formation (Figure 
5.10A) and torsional stiffness (Figure 5.10B) in the acellular the apy group compared to 
the hMSC therapy group.   
 
FIGURE 5.9:  Quantitative comparison of biomechanical prope ties of age-matched 
nude rat whole femurs with unbridged and bridged segmental defect femurs treated by 





Assessment Of 2D In Vitro AAV-LacZ Transduction Efficiency: The presence 
of blue β-galactosidase-expressing cells in all wells at both days three and six post-
transduction (Figure 5.11A,B) signified successful transduction of hMSCs by AAV-
LacZ.  Transduction efficiency was determined as the ratio of blue cells over total cells, 
which were counted in fluorescence microscopy images after DAPI nuclear stain using 
the software program ImageJ (Figure 5.11C). 
 
 
FIGURE 5.10:  Quantitative comparison of structure and functio  results from in vivo 
delivery of hMSC-seeded scaffolds or acellular scaffolds. A) In vivo mineral 
formation within defect sites.  B) Biomechanical properties of femurs tested to failure 





 Transduction efficiency increased with viral dose and with lowering the media 
volume containing the viral particles, likely do to better colocalization of the viral 
particles with the hMSCs (Figure 5.12).  Transduction efficin y also increased from day 
3 to day 6, likely due to a peak or jump in AAV transgene expression, as seen in the 
BMP2 expression of scAAV2.5-BMP2 transduced hMSCs after 6-7 days in both 2D and 
3D in vitro experiments.  The only significant differences in transduction efficiency were 
observed between the low transduction media volume / 2X AAV dose group at day 6 and 
the high transduction media volume / 1X AAV dose group at both days 3 and 6, likely 
due to the very small samples sizes.  The average initial umber of cells calculated in 
wells 24 hours after seeding was 24,321 per well, giving initial transduction multiplicity 
of infections of approximately 2*104 and 4*104.   
FIGURE 5.11:  2D in vitro transduction of hMSCs by AAV-LacZ.  A),B) hMSC β-
galactosidase expression marked by blue cells three or six days, respectively, after 
viral transduction.  Red arrows point to transduced cells.  C) DAPI-stained cell nuclei 






FIGURE 5.12:  Effects of viral dose and transduction media volume on AAV-
LacZ transduction efficiency.    
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Chapter 5: Discussion 
 
This study presents evidence that synthetic polymer scaffolds can be 
functionalized for orthotopic bone repair applications through lyophilization of scAAV 
encoding the gene for human BMP2.  The in vitro BMP2 release kinetics showed that 
transduced marrow-derived stem cells exhibited peak BMP2 release after one week in 
both 2D and 3D culture, while amniotic-fluid derived cells exhibited a delay of nearly 
two months before achieving significant BMP2 expression in 3D culture.  The hMSC 
peak release profile is advantageous for bone healing because it approximately coincides 
with the end of the inflammatory phase of long bone injury response and the initiation of 
the reparative phase of healing (Yazici, Yanoso et al. 2008).  In comparison, bolus 
delivery of recombinant proteins displays fast release kinetics that would likely occur 
during the initial inflammatory response phase of bone healing when there are many 
confounding signals present.  Furthermore, the extended BMP2 expression continued 
through at least five weeks for both stem cell types, which could lead to further mineral 
formation with time.  The BMP2 expressed by transduced hMSCs led to increases in both 
2D and 3D osteogenic outcomes, as assessed by increased ALP levels per DNA and 
increased mineral volumes per scaffold, respectively.  The increased osteogenic 
differentiation also likely resulted in reduced cell numbers as determined by DNA 
analysis, as fewer stem cells would be available to proliferate and renew the stem cell 
population.  No increases in mineral volumes were found in scAAV2.5-BMP2-
transduced hAFS Cell constructs after twelve weeks.   The fetus-derived hAFS Cells may 
be more developmentally primitive than the adult-derived hMSCs, and transduction 
efficiency differences between the two cell types, such as due to differences in AAV 
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receptor numbers or activities, may have been responsible for the osbserved differences 
in BMP2 secretion kinetics between the two sources.    
In vivo results revealed that AAV coating of PCL porous polymer scaffolds by 
lyophilization can serve as a successful vehicle for delivering genes to large bone defects.  
The preliminary study showed that direct AAV-LacZ scaffold delivery led to in vivo 
transduction of host cells surrounding the defect site whin two weeks of implantation.  
For the second segmental defect study comparing in vivo and in vitro gene therapy 
transduction methods, PCL scaffolds rather than PLDL scaffolds were used because 
various studies in our lab have found that the larger pore sizes of PCL scaffolds 
accommodate in vitro seeding and in vivo infiltration of cells better than PLDL scaffolds, 
which have smaller pore sizes (Oest, Dupont et al. 2007).  This study showed that direct 
delivery of scAAV2.5-BMP2 coated scaffolds to the defect site (in vivo gene therapy) led 
to more defect bridging than delivery of scAAV2.5-BMP2 coated scaffolds pre-seeded 
with hMSCs before implantation (in vitro gene therapy).  This may be due to a variety of 
factors such as the amount of time that cells are directly exposed to the scAAV2.5-BMP2 
vector, variability in scAAV2.5-BMP2 transduction and BMP2 expression in different 
cell types, possible loss of BMP2 expressed by hMSCs in culture prior to implantation, or 
loss of AAV particles from scaffolds into the surrounding media in culture prior to 
implantation.  Segmental defects treated by in vivo delivery of scAAV2.5-BMP2- coated 
scaffolds displayed significantly higher in vivo week 8, in vivo week 12, and post mortem 
mineral volumes as well as maximum torque and torsional stiffness compared to defects 
treated with AAV-Luc-coated scaffolds pre-seeded with hMSCs.  Defects treated with 
scAAV2.5-BMP2-coated scaffolds also displayed significantly higher in vivo week 8 and 
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post mortem mineral volumes compared to defects treated with AAV-Luc-coated 
scaffolds, although there were not significant differences in in vivo week 12 mineral 
volumes or biomechanical properties, likely due in part to the smaller sample size of the 
group (n = 6) compared to AAV-Luc-coated scaffold pre-seeded with hMSCs (n = 8).   
When in vivo and in vitro gene therapy methods were combined, defect treatment 
by scAAV2.5-BMP2 led to significantly higher in vivo and post mortem mineral 
formation at all time points as well as enhanced biomechani al properties compared to 
defects treated by AAV-Luc.  Because the maximum torque and torsional stiffness values 
of a structure depend heavily on material continuity throughout the specimen gauge 
length, defects treated with scAAV2.5-BMP2 scaffolds were divided into bridged and 
unbridged groups.  When isolated, the bridged defects displayed torsional stiffness values 
that were not significantly different from whole femurs, suggesting partial restoration of 
femoral biomechanical function.   
The results of the in vivo study refuted our initial hypothesis that treating defects 
with scaffolds providing stem cells and osteogenic signals would enhance bone repair 
over treating defects with scaffolds providing only osteogenic signals.  As a whole, 
defects treated with stem cells displayed significantly lower in vivo mineral formation at 
the study endpoint as well as significantly lower torsional stiffness than defects treated 
with acellular scaffolds, suggesting that in vivo gene therapy was superior to in vitro gene 
therapy.   The lack of stem cell-mediated repair may be due to a variety of factors 
including limited AAV transduction and / or resulting BMP2 production in hMSCs 
compared to host defect cells and the possible presence of a sufficiently large enough 
host stem cell supply to limit the contribution of the added hMSCs to the bone repair 
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process.  Furthermore, stem cells transduced with AAV prior to implantation may have 
experienced an increased immune response upon delivery as active natural killer cells 
may have responded to the virus.  Tranduction of host cellsby AAV delivered on 
scaffolds may have occurred at a later time point when t  initial inflammation stage of 
bone repair was subsiding and a more hospitable immune environment was present.  
Another unexpected result was the extremely limited repai  response in defects treated 
with AAV-Luc scaffolds pre-seeded with three million hMSCs.  While the constructs did 
not include the osteogenic cues that the scAAV2.5-BMP2 coated scaffolds provided, they 
still theoretically delivered three million viable hMSCs to the defect sites, which 
previously led to bridging in 4 / 9 defects when delivered on PCL / GFOGER / Col I 
scaffolds.  This suggests that the presence of the AAV-Luc may have actually detracted 
from the stem-cell mediated defect repair process, althoug  the mechanism of action 
remains unclear.   
Increasing viral particle dose contributed to increases in transduction efficiency as 
shown in Figure 5.12.  Coating scaffolds with a higher number of viral particles would 
likely increase the number of cells transduced and lead to increased BMP2 production.  
Increased BMP2 expression could lead to more robust mineral formation, more bridged 
defects, and full restoration of femoral biomechanical function.  In summary, the results 
presented are the first to suggest the potential for an off-the-shelf, donor bone graft-free 
therapy in which pre-sized thermostable porous polymer scaffolds lyophilized with 
scAAV2.5-BMP2 could be frozen at length until needed for clinical implantation in large 
bone defect sites.  
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Chapter 6 
SUMMARY AND FUTURE DIRECTIONS  
Overall Summary 
Bone tissue engineering therapies present an attractive treatment alternative to the 
current clinical standards of treatment with bone grafts.  These therapies generally feature 
a combination of structural scaffold, biochemical cues, and / or osteogenic or 
osteoprogenitor cells.  Therapies that include cell delivery may be especially attractive 
for treatment of large bone defects in patients such as the sick or elderly that have 
reduced supplies of endogenous cells to contribute to the bone repair process.  Stem cells 
have great potential for cellular therapy, as they possess the abilities to proliferate into 
vast cell numbers needed for repair of large defects as well as differentiate into 
osteogenic or osteoprogenitor cells.  These cells may directly participate in the bone 
healing response by forming new mineral themselves and they ma  also secrete 
biochemical cues to recruit endogenous cells to participate in forming new bone.  The 
optimal stem cell source for bone tissue engineering therapi s has not been established, 
and few studies to date have quantitatively compared stem cell sources in the same 
reproducible model of large bone defects.   
 The goal of this thesis was to establish a large bone defect model suitable for 
evaluation of human stem cell-based tissue engineering therapies and to then 
quantitatively analyze the abilities of human adult-derived and fetal-derived stem cells to 
heal defects, both in the absence and presence of osteogenic cues.  Human stem cell-
based therapies were evaluated in three ways.  First, we validated the abilities of fetal 
amniotic fluid stem cells and adult mesenchymal stem cells to form mineralized tissue in
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vitro on 3D porous polymer scaffolds and then quantitatively compared segmental defect 
healing after treatment with hMSC-seeded,  hAFS Cell-seeded, or acellular scaffolds 
(Specific Aim I - Chapter 3).  This aim directly addressed the need for direct comparison 
of various stem cell sources within the same reproducible model of large bone defect 
repair.  This challenging bone defect model could serve as a te t bed for future evaluation 
of stem cell-based bone defect repair therapies.  Second, we labeled human stem cells 
with an in vivo tracking agent, the fluorescent quantum dot, in an effort to track stem cell 
biodistribution and viability during the bone repair process.  Our results suggest that 
while post mortem immunohistochemical techniques could be used to identify delivered 
cells remaining at the defect site, quantum dots are ineffective as an in vivo cell tracking 
agent for tissue engineering therapies due to false positive ignals as well as detrimental 
effects on cell-mediated bone healing (Specific Aim II - Chapter 4).  This aim refuted the 
claimed abilities of a reportedly effective stem cell tracking agent and suggested the 
continued need for a better method for determining stem cell distribution after delivery in 
vivo.  Third, we evaluated a novel gene therapy approach for delivering osteogenic cues 
to defects by coating scaffolds with a viral vector encoding the gene for the osteogenic 
protein BMP2.  We did this by first confirming AAV in vitro stem cell transduction and 
resulting increases in osteogenic differentiation, and then utilizing the scAAV2.5-BMP2-
coated scaffolds in both in vivo (direct scaffold delivery to defect sites) and i  vitro (pre-
seeding of stem cells on scaffolds prior to implantation) gene therapy approaches for 
segmental defect repair (Specific Aim III - Chapter 5). This aim presented evidence of a 
novel delivery system of BMP2 for the repair of large bone defects, which with further 
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refinement and optimization could present a superior therapy compared to current clinical 
treatments delivering recombinant BMP2 on collagen carriers.   
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Aim I: Comparison of Adult and Fetal Stem Cell-Based Bone Tissue Engineering 
Constructs For the Repair of Large Segmental Bone Defects 
 In this Aim, we first established a challenging and reproducible model of large 
bone defects in immunocompromised rats for quantitatively comparing human stem-cell 
based tissue engineering therapies. Next we evaluated the abilities of stem cells from two 
sources, both adult marrow-derived stem cells and fetal amniotic fluid-derived stem cells, 
to form mineral when seeded on 3D porous polymer scaffolds in in vitro culture 
conditions.  Finally, we analyzed the in vivo segmental defect healing response after 
treatment with either acellular or stem-cell seeded scaffolds and found that addition of 
stem cells significantly improves defect repair.   
Stem Cell Number:  
While defects treated with stem cells experienced improved healing over defects 
treated with acellular scaffolds alone, bony bridging of defects was limited, especially in 
defects treated with hAFS Cells.  While a cellular dose f three million cells was chosen 
for the in vivo study, improved therapeutic effects might be achieved by delivering a 
higher number of stem cells.  In a skeletal muscle injury model in female Sprague 
Dawley rats, delivery of 10 million autologous MSCs led to higher restoration of muscle 
contraction forces than delivery of 2.5 million, 1 million, or 0.1 million MSCs (Winkler, 
von Roth et al. 2009).   However, there is likely a thresold stem cell number beyond 
which adding stem cells would show no benefit, as there is only a finite amount of space 
within the pore network of scaffolds for cells and mass transport limitations may only 
allow for a certain level of nutrients to be delivered to cells, beyond which cell death may 
occur. 
 124 
Co- / Pre-Seeding of Hematopoietic Stem Cells or Endothelial Cells: 
 Stem cell-mediated bone defect healing in this Aim could have been limited if 
cells were not able to obtain a sufficient enough oxygen or utrient supply to remain 
viable.  The continued viability of stem cells seeded in the cores of scaffolds may be 
especially dependent on the presence or rapid formation of a vascular network to deliver 
nutrients and prevent ischemia-related cell death.   Seeding scaffolds with hematopoietic 
stem cells or endothelial cells prior to or in parallel with seeding hMSCs or hAFS Cells 
may result in a more vascularized construct that is more c nducive to stem cell survival 
following in vivo implantation. In one recent report co-seeding of MSCs and 
hematopoietic stem cells on calcium phosphate scaffolds prior to subcutaneous 
implantation resulted in increased construct vascularization compared to MSC-seeded 
scaffolds alone (Moioli, Clark et al. 2008), while another study reported that co-seeding 
MSCs and endothelial cells on β-TCP scaffolds prior to implantation in rabbit ulnar bone 
defects resulted in superior construct vascularization and mineralization compared to 
implantation of MSC-seeded scaffolds alone (Zhou, Lin et al. 2009).   
Stem Cell Pre-Differentiation and / or Scaffold Pre-Mineralization: 
Stem cells in this Aim were delivered to defects in an undifferentiated state with 
the expectation that there would be sufficient i  situ stimuli to direct stem cells to 
differentiate down an osteogenic lineage or secrete osteoinductive factors.  However, pre-
differentiation of stem cells prior to implantation, such as by in vitro culture with 
osteogenic supplements, could increase early in vivo mineralization capacity. 
Additionally, extended in vitro culture with osteogenic stimuli could lead to mineral 
deposition throughout scaffolds prior to implantation, presenting mineral nucleation sites 
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throughout the construct.  Effects of stem cell pre-mineralization were evaluated in a 
small proof of concept preliminary in vivo segmental defect study.  Six million hAFS 
Cells were seeded on a PCL scaffold (6 mm diameter) prviously coated with lyophilized 
type I collagen as previously described.  This construct was cultured dynamically for six 
weeks in osteogenic media to differentiate hAFS Cells and induce mineral formation, and 
then the construct was scanned by Micro-CT along with a scaffold seeded with six 
million hAFS Cells two days beforehand.  One day later both constructs were implanted 
into bilateral 8 mm segmental defects created in a 20 week old female nude rat.  Twelve 
weeks later both 2D radiographs and Micro-CT scans revealed that the defect treated with 
the premineralized construct displayed reduced defect mineral formation compared to the 
defect treated with the non-predifferentiated / non-premin ralized construct (Figure 6.1).  
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Although no definite conclusions can be made with a sample size of only one, this 
preliminary experiment prompts two interesting speculations.  First, the defect treated 
with the non-premineralized scaffold experienced bony bridging as assessed by 
evaluation of 2D radiographs at the twelve week time point.  Again, delivery of six 
million hAFS Cells may lead to superior defect repair than delivery of three million 
hAFS Cells, which only led to bony bridging in 1/9 segmental defects (Specific Aim I / 
Figure 3.6).  Second, the premineralized defect displayed poor defect healing, which may 
be due to a reduction in stem cells present at the time of implantation.  As described in 
Specific Aim III, stem cell-seeded constructs that displayed the highest mineral volumes 
FIGURE 6.1:  Effects of stem cell premineralization on segmental defect healing.  
Micro-CT scans of hAFS Cell-seeded PCL scaffolds one day pre-surgery (left) and 
resulting segmental defect repair 12 weeks after implantatio  (right).  
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were found to contain the lowest amounts of DNA, suggesting lower numbers of cells 
(Figure 5.4, Figure 5.5) compared to groups displaying less mineral.  As stem cells 
seeded on the scaffolds differentiate into osteogenic cells or osteogenic precursors, the 
number of proliferating stem cells is likely reduced.  The increased scaffold mineral 
volume at the time of implantation may be less important o defect healing than the initial 
number of stem cells present.  Furthermore, cells contained within pre-mineralized tissue 
may be more isolated from biochemical cues at the defect site, and mineral may form a 
barrier between cells and the ingrowing vascular supply, impeding mass transport and 
affecting cell viability within the scaffold.  The results of this pilot study are in agreement 
with a previous report that culture of MSCs in osteogenic media for 16 days prior to 
implantation into a critically-sized rat cranial defect (pre-mineralization) decreased the 
healing response compared to treatment with undifferentiat d MSCs.  However, short-
term culture in osteogenic media for 4 days prior to implantation (pre-differentiation) led 
to an improved healing reponse compared to undifferentiated MSCs (Castano-Izquierdo, 
Alvarez-Barreto et al. 2007).  In another in vitro study, pre-mineralization of titanium 
scaffolds prior to seeding hMSCs led to increases in osteogenic differentiation compared 
to hMSCs seeded on plain titanium scaffolds, as assessed by calcium content (Pham, 
Kasper et al. 2008). 
Stem Cell Delivery Vehicle: 
 The experiments performed in this study showed that PCL scaffolds coated with 
GFOGER and lyophilized type I collagen could serve as an efficient structural network 
for stem cell attachment followed by mineral formation.  While PCL degrades in vivo 
through hydrolysis, histological evaluation of femoral defect sections performed 12 
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weeks post-surgery clearly showed the presence of PCL scaffold remaining at the defect 
site (Figure 4.7A).  While scaffolds serve as an initial structural framework on which new 
mineral can form, they could also impede further bone formation by occupying space 
within the defect.  Some reports have estimated the time for complete resorption of PCL 
scaffolds to be approximately 24 months and possibly longer depending on specific 
geometries and in vivo environments (Meyer and Wiesmann 2006). Use of a porous 
polymer scaffold with faster degradation kinetics could ensure that new bone formation is 
not impeded by remaining scaffold material, as could cellular delivery in a fibrin or 
alginate gel or delivery of cells seeded on a 2D cylindrical mesh tube.  
Stem Cell Delivery Timing:   
 As mentioned previously, the initial phase of the healing response to long bone 
injuries is an inflammatory phase during which there are a variety of confounding signals 
present that may be detrimental to differentiation of delivered stem cells (Yazici, Yanoso 
et al. 2008).  If stem cell delivery were delayed until the initiation of the reparative phase 
of bone healing which begins approximately one week after initial injury, then the cells 
might be implanted into a more hospitable environment which could facilitate 
differentiation and enhance bone repair (Meijer, de Bruijn et al. 2007).  A similar delayed 
ESC-derived cardiomyocyte delivery has been advocated for repair of heart tissue after 
infarction (Laflamme and Murry 2005).  Delayed delivery could be accomplished by first 
creating empty defects, closing the wound sites, and then reopening them a week or two 
later to deliver stem cell-seeded scaffolds.  A biocompatible cylindrical plug or spacer 
could be inserted into the defect space to preserve an open volume for later scaffold 
insertion.    
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Immunosuppression:   
 As mentioned in Chapter 3, nude rats lack T cells but stillpossess other 
lymphocytes such as natural killer cells and B cells.  While there were no gross signs of 
an immune response caused by implantation of xenogeneic hMSCs or hAFS Cells, it is 
still possible that they elicited some form of immune response detrimental to stem cell 
survival and osteogenic differentiation. In a recent study hAFS Cells were rejected after 
application in rat myocardium in both immunocompetent and in immunocompromised 
rats (Chiavegato, Bollini et al. 2007).  Therefore the addition of an immunosuppressant 
such as anti-asialo GM1 antibody, which specifically blocks natural killer cell activity 
(Kasai, Yoneda et al. 1981), could possibly enhance human stem cell viability and cell-
mediated bone defect repair. 
Mechanical Loading:  
 Defects in this study were predominantly shielded from mechani al loads by stiff 
polysulfone bridging plates.  Because increased strains from mechanical loading can 
enhance cell-mediated bone modeling, use of a bridging plate with some level of 
compliance could stimulate delivered cells to increase def ct repair.  We have recently 
modified our bridging plate design to allow for controlled in vivo axial loading of defect 
sites, however the design has currently only been used in combination with acellular 
treatments (Boerckel, Dupont et al. 2009).  
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Aim II: Tracking Delivered Human Stem Cells During The Segmental Defect 
Healing Process 
In this Aim, we sought to label stem cells with an in vivo tracking agent in order 
to track their biodistribution and viability during the segmental defect repair process.  We 
chose quantum dots as our in vivo tracking agent based upon favorable reports in the 
literature and successful short-term in vitro experiments suggesting a strong potential for 
in vivo fluorescence imaging detection as well as a lack of observed detrimental effects 
on cell viability and function.  However, application in segmental defect studies revealed 
the quantum dot as a poor choice for long term in vivo cell tracking during large bone 
defect repair due to false positive signals caused by QD transfer to host cells as well as a 
detrimental effect on the bone healing process.  A small population of delivered human 
cells was identified at the defect site through post mortem histological immunostaining 
performed four weeks after cell delivery.  
In Vivo Cell Tracking Agent:   
 As mentioned above, quantum dots failed to satisfactorily track labeled stem cells 
throughout the defect repair process, suggesting the need for an alternative in vivo cell 
tracking agent.  One possible option that has been described is the genetic modification of 
MSCs with the genes for both luciferase (Luc) and green fluorescent protein (GFP) 
expression (Blum, Temenoff et al. 2004), (Day, Kawecki et al. 1998), (Hara, Murakami 
et al. 2008).  This dual-labeling option is advantageous because after stem cells are 
introduced to a gene delivery vector, the population of stem cells that has been 
successfully labeled with the transgene for GFP could be isolated by fluorescence 
activated cell sorting (FACS).  Next this GFP positive cell population could be used for 
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in vivo implantation and tracking with the knowledge that delivered cells should also 
express luciferase, increasing the chances of in vivo bioluminescence detection.  
Furthermore, if the labeled cells died they would cease to xpress a bioluminescent 
signal, meaning that a continued bioluminescent signal would indicate presence of viable 
stem cells without the chance of the false positive signals that discouraged the continued 
use of quantum dots.  Additionally, retrovirally dual-labeled Luc / GFP MSCs have been 
shown to retain the capacity to osteogenically differentiate and increase in vivo bone 
formation (Olivo, Alblas et al. 2008).  This cell tracking option would possess many 
desirable traits for an in vivo cell tracking agent, however, the safety and biocompatibility 
of such as system would need to be evaluated prior to and during long term in vivo use 
due to the genetic modification of cells and the requirement for injection of luciferin prior 
to bioluminescence imaging.   
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Aim III: Adeno-Associated Viral Vector Transduction of Human Stem Cells with 
Osteogenic Cues To Enhance Bone Formation 
 In this Aim, we first evaluated the ability of porous polymer scaffolds bioactivited 
through adeno-associated virus lyophilization to transduce cells at segmental defect sites.  
Next we confirmed that AAV encoding the osteogenic gene BMP2 could successfully 
transduce human stem cells in vitro eliciting their osteogenic differentiation.  Finally we 
compared segmental defect repair after treatment with AAV-BMP2 coated scaffolds or 
AAV-BMP2 coated scaffolds pre-seeded with hMSCs.  Only the in vivo gene therapy 
approach of direct AAV-BMP2 scaffold delivery led to significantly better defect repair 
than treatment with control scaffolds.   
Viral Particle Dose:  
 Seeding one million hMSCs on PCL scaffolds coated with1010 scAAV2.5-BMP2 
viral particles led to stem cell transduction as measured by secreted BMP2 levels (Figure 
5.3) and resulted in increased in vitro mineral formation within scaffolds (Figure 5.4).  
However, seeding three million hMSCs on similar scaffolds failed to significantly 
increase in vivo mineral formation in segmental defects.  The lack in vivo mineral 
formation may be due to a multiplicity of infection that was only one third of that used in 
the in vitro study (0.333 * 104 versus 104).   As described in Chapter 5, using a higher 
viral particle dose resulting in a higher MOI contributes to increased transduction 
efficiency in hMSCs (Figure 5.13).  Assuming that scaffolds would not experience a loss 
in viral particles as coating density increased, then tripling the number of scAAV2.5-
BMP2 particles coated onto scaffolds for in vivo implantation would produce an equal 
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MOI to that used in 3D in vitro experiments and possibly lead to further in vivo mineral 
production from transduced hMSCs.  A viral particle dose response segmental defect 
experiment where scaffolds were coated with different quantities of AAV prior to seeding 
hMSCs and implanting into defect sites would help to establish the relationship between 
AAV MOI and in vivo healing capacity.  Additionally, a study should be performed to 
evaluate viral particle retention efficiency with varying scaffold coating densities to 
reduce the likelihood of loss of viral particles from scaffolds prior to stem cell 
transduction.   
Co-Delivery of Multiple Viral Vectors:  
 While the BMPs have proven to be some of the most potent osteoinductive 
proteins, a variety of other proteins play key roles during the bone repair process and 
their delivery could enhance the defect repair process.  BMP2 and TGF-β co-delivery 
were previously shown to synergistically enhance in vivo ectopic mineralized matrix 
formation in a murine model compared to treatment with either growth factor alone 
(Simmons, Alsberg et al. 2004).  Coating scaffolds with the genes encoding both proteins 
could lead to a similar enhancement of segmental defect repair.   
 One particular concern in treating large bone defects with high quantities of stem 
cells seeded throughout scaffolds is the possible loss of viability.  After implantation a 
key element in maintaining stem cell viability is the development of a vascular network 
throughout the scaffold to provide cells with oxygen and nutrients crucial to their survival 
(Meijer, de Bruijn et al. 2007).  Rapid formation of a vascular network may be especially 
important for translational therapies where bone tissue engineering constructs would have 
to be scaled up for treatment of larger human bones, as stem cells at the center of 
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constructs could initially be millimeters or even centimeters away from a vascular supply.  
Delivery of oxygen and nutrients to cells by diffusion alone would be insufficient, 
creating a rapid loss in viability of delivered cells.  To facilitate vascular network 
development, delivered stem cells could be transduced by AAV encoding not only 
osteogenic BMP2 but also an angiogenic protein such as vascular endothelial growth 
factor (VEGF).  A similar approach was previously reported in which rat subcutaneous 
implantation of PLG scaffolds co-delivering the recombinant proteins VEGF and PDGF 
led to significantly higher scaffold vascular invasion than scaffolds delivering either 
protein alone (Richardson, Peters et al. 2001). 
In Vivo Segmental Defect Study Duration: 
 The in vivo segmental defect studies described in this study did not exceed twelve 
weeks in duration.  Our previous segmental defect studies in Sasco Sprague Dawley rats 
(Oest, Dupont et al. 2007), (Rai, Oest et al. 2007) have shown that the majority of in vivo 
mineral formation occurs within the first eight weeks of the study, and changes between 
eight and twelve weeks are minimal.  This trend was ob erved in the segmental defect 
study described in Chapter 1 delivering adult or fetal stem cells s eded on porous 
polymer scaffolds (27.86 mm3 week 8 versus 29.66 mm3 week 12, hMSCS / 19.06 mm3 
week 8 versus 21.76 mm3 week 12, hAFS Cells) (Figure 3.7A).  When treating defects 
with scAAV2.5-BMP2 coated scaffolds, with or without pre-seeded hMSCs, there is the 
possibility that extending the study duration to sixteen or twenty weeks would lead to 
increases in in vivo bone volume.  AAV-delivered genes may be expressed by transduced 
cells throughout their entire lifetimes.  Extending study duration may be especially 
important if defects were treated with scAAV2.5-BMP2 transduced hAFS Cells due to 
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their observed BMP2 release kinetics (Figure 5.3), which dsplayed significantly higher 
BMP2 levels than AAV-Luc transduced cells throughout nearly the entire 12-week study, 
and especially high levels during a peak lasting between w eks seven and ten post-
transduction.  This extended-duration osteoinductive protein releas  could lead to 
increases in in vivo mineral formation for weeks after that, suggesting the ne d for a 
longer study length.   
MSC Implantation Into Immunocompetent Sasco Sprague Dawley Rats: 
 As described in Chapter 3, 13-week old female nude rats used in these studies are 
generally smaller than age-matched female Sasco Sprague Dawl y rats (Figure 3.3) that 
we have used previously in acellular segmental defect therapies.  In addition to 
differences in size, there could also be differences in the ways that the two rat strains 
respond to biochemical factors (Kacew, Ruben et al. 1995).  As described previously, 
both MSCs and AAV may be non-immunogenic, so they could theoretically still be used 
to effectively treat defects in immunocompetent SSD rats.  However, allogeneic rat 
MSCs may need to be used rather than xenogeneic human MSCs to avoid cell rejection.  
Successful treatment of defects in SSD rats with allogeneic MSC / AAV treatments 
would support use of allogeneic human MSCs and AAV to treatbone defects in humans, 




Challenging large bone defects and nonunions pose a clinical problem that 
currently lacks an adequate therapeutic solution.  Bone tissue engineers aim to provide 
that solution, and tissue engineering therapies that include a cellular component are likely 
necessary for effective treatment of severe defects in patients lacking sufficient 
endogenous cell populations.  While autologous stem cell therapies can enhance the large 
bone defect healing response, allogeneic stem cell delivery may be necessary for treating 
those patients with limited autologous supplies or in cases where there is not sufficient 
time to harvest, expand, and reimplant autologous cells.  However, there have currently 
been few preclinical studies that quantitatively compared therapies using different stem 
cell sources in the same large bone defect model.  Maximizing therapeutic effects by 
selecting a preferred stem cell source and delivery method in preclinical studies will 
facilitate translation of stem cell therapies to clini al applications.   
The central theme of the work in this thesis consisted of developing a novel 
challenging model of large bone defects for quantitative comparison of human stem cell-
based therapies, and then evaluating the abilities of both adult and fetal stem cell-seeded 
constructs to enhance defect repair, both with and without added osteogenic stimuli.  Our 
hypothesis that treatment of large bone defects with stem cell-seeded constructs would 
increase bone repair over treatment with acellular constructs in the absence of added 
osteogenic stimuli was validated; however, no clear advantage was discerned between 
defect treatment with adult marrow-derived stem cell versus fetal amniotic fluid-derived 
stem cell constructs.  The lack of individual differences in defect healing between adult 
hMSC-seeded scaffold treatment, fetal hAFS Cell-seeded scaffold treatment, and 
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acellular scaffold treatment is possibly due to endogenous host cell contributions to 
repair, to the high variability in repair outcomes within treatment groups, and to a small 
therapeutic effect size of the stem cell treatments compared to that of osteogenic protein 
delivery, which we have observed previously in a similar immunocompetent rat 
segmental defect model.  
Our attempts to non-invasively track delivered stem cells in vivo throughout the 
defect repair process were unsuccessful due to the limitations of our cell tracking agent, 
thus preventing us from verifying our hypothesis that a portion of delivered cells would 
remain viable at the defect site throughout the study to contribute to bone repair.  
Although post mortem analysis with immunohistochemistry indicated that some human 
stem cells remained at the defect site four weeks after implantation, the vast majority of 
cells were no longer there, suggesting the need for a better delivery system.  However, 
our studies generated the valuable finding that the fluorescent quantum dot, previously 
reported to potentially be an excellent i  vivo cell tracking agent, should not be used for 
long term cell tracking during bone repair due to its internalization into host cells, thus 
creating a false positive signal, and its possible detrimntal effects on bone repair.  This 
work suggests that continued emphasis on improved cell delivery and tracking methods 
are required if long term viability and engraftment of delivered cells is to be achieved. 
Our hypothesis that delivery of osteogenic cues to defect sites would enhance 
defect healing was confirmed, as scAAV2.5-BMP2 treatment groups displayed 
significantly more defect mineral formation and mechanicl properties than AAV-Luc 
treatment groups.  Our hypothesis that bone repair would be enhanced by the combined 
treatment of stem cells and osteogenic cues was denied, with implantation of acellular 
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scAAV2.5-BMP2 coated scaffolds resulting in increased defect bridging compared to 
implantation of scAAV2.5-BMP2 coated scaffolds pre-seeded with hMSCs.  This finding 
does not rule out the possibility that scAAV2.5-BMP2 scaffold / hMSC treatments could 
be effective at treating large bone defects, as increases in viral particle number or stem 
cell delivery into elderly or sick patients lacking endogenous cell supplies may elicit 
improved cell-mediated responses.  However, this finding does present the first evidence 
of a novel acellular orthotopic bone tissue engineering therapy with the potential for off-
the-shelf clinical application in treating large bone defects or nonunions, as biodegradable 
porous polymer scaffolds of varying sizes could be coated by thermostable scAAV2.5-
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